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ABSTRACT  
Type 1 diabetes is an autoimmune disease, in which insulin-producing ?-cells 
in the pancreas are destroyed leading to a life-long external insulin-
dependency. Finland has the highest incidence of type 1 diabetes in the 
world, increasing almost 5-fold since the 1950s. The reasons for this increase 
are not known, therefore it is not possible to delay or prevent the disease. 
Identifying the factors that can modify the disease risk and interfere with the 
disease process is highly important, since despite advances in disease 
management, the life expectancy of patients with type 1 diabetes is estimated 
as more than 10 years shorter than that of the normal population.  
Type 1 diabetes develops as a result of complex interactions between 
genetic and environmental factors. While more than 50 genetic loci 
associated with type 1 diabetes risk have been identified the strongest risk is 
conferred by the human leukocyte antigen (HLA) gene region. The 
environmental factors, however, remain unknown. Epidemiological evidence 
suggests an association between vitamin D and type 1 diabetes, but 
information on the actual vitamin D status (serum 25-hydroxyvitamin D 
(25OHD) concentration) during pregnancy or childhood prior to diagnosis is 
scarce. Genes in the metabolic pathway of vitamin D are associated with type 
1 diabetes, but the interaction between vitamin D status, vitamin D related 
genetic factors and type 1 diabetes is poorly known.  
We investigated the association between vitamin D and type 1 diabetes by 
determining maternal vitamin D status in a retrospectively case-control 
study setting, when it was already known which of the children later 
developed type 1 diabetes. We utilised a unique sample collection, the 
Finnish Maternity Cohort (FMC) that collects serum samples of almost every 
pregnancy in Finland. We evaluated the association between single 
nucleotide polymorphisms (SNPs) in the metabolic pathway of vitamin D and 
type 1 diabetes. Furthermore, we investigated the relationship between 
vitamin D status and the HLA gene region.   
No difference in maternal serum 25OHD concentrations emerged 
between mothers of diabetic and non-diabetic children (43.9 nmol/l and 43.5 
nmol/l; n=686). Around 70% of all pregnant women were vitamin D 
deficient (serum 25OHD concentration < 50 nmol/l). We found novel proof 
of a relationship between maternal genetic factors in the metabolic pathway 
of vitamin D and type 1 diabetes risk in the child. The genotypes of two SNPs 
located in the vitamin D receptor (VDR) gene showed different genotype 
distribution between mothers whose children later developed type 1 diabetes 
and those whose did not. The VDR regulates the transcription of hundreds of 
vitamin D target genes.  
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We also found for the first time that associations between serum 25OHD 
concentration and SNPs in the VDR and the group-specific component (GC) 
were stronger during pregnancy in mothers whose children later developed 
type 1 diabetes than in mothers whose children did not. The GC gene encodes 
vitamin D binding protein to which vitamin D is attached during circulation. 
Furthermore, we found a novel association between serum 25OHD 
concentration and the HLA gene region. A group of HLA alleles (HLA-B44 
supertype) associated with low serum 25OHD concentration. 
Our results do not support a direct association between maternal vitamin 
D status and type 1 diabetes risk in the child. It may be, however, that we 
were not able to detect a possible protective effect of vitamin D in this 
population since a considerable proportion of all mothers were vitamin D 
deficient. Our results demonstrate novel differences in genetic factors related 
to the metabolic pathway of vitamin D during pregnancy between mothers 
whose children later developed type 1 diabetes and whose did not. The found 
relationship between the HLA gene region and vitamin D status indicates an 
even stronger role for vitamin D in the immune system than previously 
thought.  
Our results suggest that more attention should be paid to the mother and 
pregnancy, when investigating the early programming of type 1 diabetes. 
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TIIVISTELMÄ 
Tyypin 1 diabetes on autoimmuunisairaus, jossa insuliinia tuottavat haiman 
?-solut tuhoutuvat. Tämä johtaa elinikäiseen ulkoisen insuliinin tarpeeseen. 
Suomessa tyypin 1 diabeteksen ilmaantuvuus on viisinkertaistunut viidessä 
vuosikymmenessä ja on korkeampi kuin missään muualla maailmassa. Syitä 
ilmaantuvuuden kasvuun ei tunneta ja täten taudin ehkäisy ei ole vielä 
mahdollista. Taudin syntyyn vaikuttavien tekijöiden tutkiminen on tärkeää, 
sillä vaikka tyypin 1 diabeteksen hoito on kehittynyt, potilaiden 
eliniänodotteen on arvioitu olevan edelleen yli 10 vuotta normaaliväestöä 
alhaisempi. 
Tyypin 1 diabeteksen puhkeamiseen vaikuttaa sekä perinnöllinen alttius, 
ympäristötekijät että näiden yhteisvaikutus. Taudin riskiin vaikuttavia 
perinnöllisiä tekijöitä tunnetaan yli 50, joista suurin vaikutus on HLA-
geenialueella. Ympäristötekijöitä ei ole vielä pystytty varmuudella 
tunnistamaan. D-vitamiinin ja tyypin 1 diabeteksen yhteydestä on 
epidemiologista näyttöä, mutta diagnoosia edeltävistä D-vitamiinitasoista 
(seerumin 25-hydroksi-D-vitamiini; 25OHD) on vain vähän tietoa. Tietyt D-
vitamiinin aineenvaihduntaan osallistuvat geenit ovat yhteydessä tyypin 1 
diabetekseen. D-vitamiinitason, D-vitamiinin aineenvaihduntaan 
osallistuvien geenien ja tyypin 1 diabeteksen vuorovaikutus tunnetaan 
kuitenkin vielä huonosti.  
Tavoitteemme oli tutkia äidin raskaudenaikaisen D-vitamiinistatuksen 
yhteyttä lapsen riskiin sairastua tyypin 1 diabetekseen jälkikäteen, kun jo 
tiesimme ketkä lapsista myöhemmin sairastuivat ja ketkä eivät. Meillä oli 
mahdollisuus käyttää ainutlaatuisen Finnish Maternity Cohort (FMC) 
näytekokoelman näytteitä. FMC-seerumipankkiin on kerätty näyte lähes 
kaikilta raskaana olevilta suomalaisilta vuodesta 1983 alkaen. Tutkimme 
myös useiden D-vitamiinin aineenvaihduntaan osallistuvien geenien 
pistemutaatioiden (single nucleotide polymoprhisms; SNPs) yhteyttä tyypin 1 
diabetekseen. Lisäksi tutkimme HLA-geenialueen ja D-vitamiinistatuksen 
yhteyttä.  
Diabeetikoiden ja terveiden lasten äitien raskaudenaikaisissa seerumin 
25OHD-pitoisuuksissa ei ollut eroa (43.9 nmol/l ja 43.5 nmol/l; n=686). 
Noin 70 %:lla sekä diabeetikoiden että terveiden lasten äideistä oli 
raskaudenaikainen D-vitamiininpuutos (seerumin 25OHD-pitoisuus < 50 
nmol/l). Löysimme uutta tietoa äidin D-vitamiinin aineenvaihduntaan 
osallistuvien geenien yhteydestä lapsen riskiin sairastua tyypin 1 
diabetekseen. Kahden D-vitamiinireseptorissa (VDR) sijaitsevan SNP:n 
genotyyppijakauma oli erilainen diabeetikoiden ja terveiden lasten äideillä. 
VDR välittää D-vitamiinin vaikutukset sen satoihin kohdegeeneihin.  
Havaitsimme myös ensimmäistä kertaa että diabeetikoiden äideillä VDR- 
ja GC-geeneissä (group-specific component) sijaitsevat SNPt yhdistyivät 
 7 
voimakkaammin seerumin 25OHD-pitoisuuteen raskauden aikana kuin 
terveiden lasten äideillä. GC koodaa D-vitamiinin kuljetuksessa tarvittavaa 
proteiinia (DBP). Löysimme myös uuden yhteyden seerumin 25OHD-
pitoisuuden ja HLA-geenialueen välillä. Ryhmä kudostekijöitä (HLA-B44 
supertyyppi) yhdistyi matalaan seerumin 25OHD-pitoisuuteen.   
Tutkimuksessamme ei löydetty suoraa yhteyttä äidin raskaudenaikaisen 
D-vitamiinitason ja lapsen diabetesriskin välillä. Saattaa olla, että D-
vitamiinin mahdollinen suojavaikutus jäi näkymättä tässä tutkimusjoukossa, 
koska D-vitamiinin puutos oli huomattavan yleistä kaikilla äideillä. 
Diabeetikoiden ja terveiden lasten äidit olivat kuitenkin erilaisia tiettyjen D-
vitamiinin aineenvaihduntaan osallistuvien geenien osalta. Löydetty yhteys 
HLA-geenialueen ja D-vitamiinitason välillä korostaa D-vitamiinin 
merkittävää roolia puolustusjärjestelmän säätelijänä.  
Tuloksemme viittaavat siihen, että äitiin ja raskauteen liittyviin tekijöihin 
tulisi kiinnittää enemmän huomiota kun tutkitaan tyypin 1 diabeteksen 
varhaista ohjelmoitumista.  
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1 INTRODUCTION 
Before starting this work, I once read that type 1 diabetes is a researcher´s 
nightmare. Back then, a wide selection of both genetic and environmental 
factors had been introduced to explain the pathogenesis of the disease. 
Nevertheless, the researchers did not seem to have a clue why the incidence 
of type 1 diabetes kept increasing especially in the western world. 
Now, some years and a lot of research later, we are faced with the same 
question. While genetic research has now identified over 50 susceptibility 
loci for type 1 diabetes (Onengut-Gumuscu et al, 2015), we still do not know 
what initially causes ?-cells in the pancreas to be destroyed by an 
autoimmune reaction. We also still have not been able to identify with 
certainty the environmental factors that modify the risk. Thus, we still do not 
have means to delay, stop or reverse the disease process of type 1 diabetes. 
When we started to plan the “Vitamin D and Type 1 Diabetes” study the 
extent of ongoing vitamin D research was a lot smaller. A few high-quality 
studies existed, however, indicating that the intake of vitamin D from 
supplements during pregnancy or infancy may modify the risk for type 1 
diabetes in the child (Hyppönen et al, 2001; Stene et al, 2000). Since the 
vitamin D status (serum 25-hydroxyvitamin D; 25OHD concentration) is, in 
addition to vitamin D supplement use, strongly influenced by the amount of 
UV radiation and to some extent dietary factors, we thought it would be 
interesting to measure the actual serum 25OHD concentrations during 
pregnancy to evaluate the association between maternal vitamin D status and 
type 1 diabetes risk in the child. We had the privilege of using a unique 
sample collection, the Finnish Maternity Cohort (FMC) containing serum 
samples from almost all pregnancies in Finland since 1983. Therefore, we 
had the possibility to analyse maternal serum 25OHD concentrations 
retrospectively, when type 1 diabetes development in the children was 
already known.   
When planning the study, existing research suggested that genes in the 
metabolic pathway of vitamin D also contribute to the inherited risk for type 
1 diabetes (Lopez et al, 2004; Pani et al, 2000). The human leukocyte antigen 
(HLA) gene region was already known to be a strong genetic component in 
the disease aetiology (Nerup et al, 1974). To investigate not only an 
epidemiological association between maternal vitamin D status and type 1 
diabetes, but also a potential mechanism explaining the possible association, 
we decided to include genetic analyses in our project. 
This thesis evaluates the role of maternal vitamin D status during 
pregnancy for the risk for type 1 diabetes in the child. It also presents results 
of the differences in genetic factors in the metabolic pathway of vitamin D 
between mothers whose children later develop type 1 diabetes and those 
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whose do not. In addition, this thesis evaluates the relationship between the 
HLA gene region and vitamin D status.  
Review of the literature 
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2 REVIEW OF THE LITERATURE 
2.1 TYPE 1 DIABETES 
 
2.1.1 TYPE 1 DIABETES IN FINLAND 
Type 1 diabetes is a complex autoimmune disease, in which the 
insulin-producing ?-cells in the pancreas are destroyed in a predominantly T 
cell mediated process. Insulin is needed to move sugar from the blood into 
cells to be used as an energy source. The lack of insulin leads to an increased 
blood sugar concentration and therefore a life-long exogenous insulin 
dependency. 
Usually around 80% of the insulin-producing ?-cells have been destroyed 
by an autoimmune reaction when the disease is diagnosed (Foulis et al, 
1986), but the autoimmune process leading to the clinical disease can last 
years or even decades before diagnosis (Knip et al, 2010). Type 1 diabetes 
accounts for approximately 5-10% of all diabetes and is one of the most 
common chronic diseases in children, but it can be diagnosed at any age 
(American Diabetes Association, 2017; Gale, 2005).  
For the patient or their families, the incurable disease requires constant 
monitoring and care. The treatment of type 1 diabetes consists of monitoring 
of the blood sugar concentration, a personal insulin treatment regimen with 
both rapid-acting and long-acting insulin, as well as diet and exercise 
planning. The development of continuous glucose monitoring systems, small 
wearable devices that continuously track blood glucose concentration and 
notify when the blood sugar is too low or high, have proven to be beneficial 
for a considerable part of the patients in their disease management (Beck et 
al, 2017; Lind et al, 2017). Presently, only a small portion of the type 1 
diabetic patients in Finland have access to these devices 
(www.diabetes.fi/diabetesliitto). 
Information on the health care costs that are particular to type 1 diabetes 
is scarce. It is known that around 10% of all health care costs in Finland 
during 1998-2007 were related with diabetes (any type of diabetes) (Jarvala 
et al, 2010). 
 Inequalities between the developing countries and the western world 
mean that patients with type 1 diabetes face different challenges in different 
countries. In the developing countries access to insulin and the technology 
needed for disease management may be a problem, whereas in the western 
world the patients may suffer from long-term macrovascular (such as an 
increased risk for cardiovascular events) and microvascular (such as 
retinopathy and nephropathy) complications (Atkinson et al, 2014). 
Considering the costs for the health care system and the considerable 
psychological burden of the disease for the patients and their families 
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(Hagger et al, 2016; Whittemore et al, 2012), identifying modifiable factors 
that can interfere with the disease process is extremely important.  
Type 1 diabetes occurs worldwide, but differences in incidence are 
substantial between different countries with the highest reported incidence 
in Finland (DIAMOND Project Group, 2006; Harjutsalo et al, 2008; 
Harjutsalo et al, 2013). Countries or geographical regions in close proximity 
may have substantial differences in the disease incidence. For example, a 
considerably higher incidence occurs in Finland than in Estonia/Russia and 
Sardinia and other parts of Italy (Borchers et al, 2010a; DIAMOND Project 
Group, 2006; Kondrashova et al, 2005; Podar et al, 2001). Some of the 
geographical variation in type 1 diabetes incidence may result from 
differences in the predisposing genetic factors, especially differences in the 
HLA gene region (Rønningen et al, 2001; Tuomilehto, 2013). The presence of 
predisposing environmental factors and/or the absence of protective 
environmental factors also contributes (Kondrashova et al, 2007; Rewers and 
Ludvigsson, 2016). 
Type 1 diabetes incidence is increasing in many western countries with 
around a 2-4% annual increase (Harjutsalo et al, 2008; Patterson et al, 2009; 
Vehik et al, 2007). In Finland, the first nationwide incidence estimation in 
the 1950s showed an incidence of 13 per 100 000 persons under 15, whereas 
in 2011 the incidence was almost 5-fold (Harjutsalo et al 2013; Tuomilehto, 
2013) (Figure 1). The reasons for this considerable increase in type 1 diabetes 
incidence in Finland remain unknown. It has been shown though, that the 
incidence in the younger age groups in Finland has increased even more than 
in the older age groups possibly reflecting a shift in the clinical onset of the 
disease to younger age groups (Harjutsalo et al, 2008). After a peak 
incidence of 64.9 per 100 000 persons in children younger than 15 in 2006, 
the increase in the incidence seems to have leveled out (Harjutsalo et al, 
2013). It may be too early to draw a conclusion on whether the leveling of the 
incidence is a temporary phenomenon, or whether it indicates an actual 
decrease in the disease incidence caused by environmental factors.  
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Figure 1. Incidence of type 1 diabetes in Finland per 100 000 persons under 15 years of age 
(Harjutsalo et al, 2008; Harjutsalo et al, 2013; Somersalo et al, 1954-5; Tuomilehto et al, 1999). 
 
 
 
2.1.2 ENVIRONMENTAL TRIGGERS NOT REVEALED 
The steady increase in type 1 diabetes incidence especially in the western 
world indicates an impact of environmental factors in the disease 
pathogenesis that have changed. Presence of these environmental factors in 
the disease pathogenesis is evidenced by the observation that migrants 
acquire a disease risk equal to the population in their new area of residence 
(Söderström et al, 2012). These environmental triggers act during the foetal 
period and/or childhood either independently or through interactions with 
genetic factors, and they determine whether or not the genetically susceptible 
individuals develop type 1 diabetes.  
An increasing incidence of type 1 diabetes means that an increasing 
proportion of the new patients do not carry a high genetic risk for the disease 
(Hermann et al, 2003; Steck et al, 2011). Environmental triggers are difficult 
to identify because there may be an unknown critical time window for a 
specific environmental exposure. The most studied environmental factors in 
the pathogenesis of type 1 diabetes are infections, diet and more recently, gut 
microbiota. 
A role for certain viral infections in the disease pathogenesis has been 
suggested for decades and justified for example based on a finding that 
viruses can cause diabetes in animals (Yoon et al, 2006).  
Enteroviruses have been detected in the pancreatic islets of newly-
diagnosed type 1 diabetes patients indicating a role in the destruction of the 
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?-cells (Krogvold et al, 2015). In Finland, the detection of viral RNA in serum 
or stool is associated with the risk for type 1 diabetes (Hyöty, 2016). An 
infection of a certain type of enterovirus, coxsackievirus B1, is also associated 
with an increased risk for the occurrence of autoantibodies that precede the 
clinical onset of the disease (Laitinen et al, 2014). Increased sanitation and 
hygiene, along with economic growth, has in many countries gone hand in 
hand with the increase in the incidence of type 1 diabetes (Bach, 2002). It has 
been suggested that a decreasing frequency of childhood infections leads to 
defects in the establishment of immune tolerance, and therefore a higher 
incidence of type 1 diabetes and other immune system mediated diseases 
(Bach, 2002). The existing research, however, has been unable to confirm 
this theory. Though, it is possible that the detected decrease in the 
enterovirus infections during pregnancy leads to children not receiving 
maternal protecting antibodies and experiencing their first enterovirus 
infection later with harmful consequences (Viskari et al, 2005).  
Many studies have detected differences in the gut microbiota between 
type 1 diabetic patients and healthy controls (Bibbò et al, 2016; de Goffau et 
al, 2014; Giongo et al, 2011). The human gut microbiota has changed 
considerably during the past decades, resulting from several factors such as 
changes in the diet, improved hygiene and increased use of antibiotics 
(Quercia et al, 2014). For decades, there has been an attempt to find means 
to modify the gut microbiota to improve the health of the host for example by 
using probiotics and prebiotics. Probiotics are defined as live 
micro-organisms that confer a health benefit on the host, whereas prebiotics 
are substances that allow changes in the growth or activity of beneficial host 
micro-organisms (Roberfroid, 2007; Schlundt, 2012). The prebiotic 
compounds in breast milk affect the colonisation of the infant gut (Zivkovic 
et al, 2011). In a recently published study including samples from Finland it 
was shown that early exposure (0-27 days after birth) to probiotics decreased 
the risk for autoimmunity by 60% in children with a high genetic risk for type 
1 diabetes compared to a later probiotic supplementation or to no 
supplementation at all (Uusitalo et al, 2016). These studies suggest that the 
gut microbiota of an infant can be modified and that the modification may 
decrease type 1 diabetes risk. The studies in the field are at the moment still 
mainly small and observational by nature, however, and the precise 
mechanism between the gut microbiota and risk for type 1 diabetes risk is 
lacking.  
Other environmental triggers that have been linked to increased risk for 
type 1 diabetes relate closely to the gut microbiota, such as breastfeeding, 
diet, enterovirus infections and antibiotic exposure (Koenig et al, 2011). 
Therefore, it has been suggested that the associations between these 
environmental factors and type 1 diabetes may be explained by their effect on 
the gut microbiota (Gülden et al, 2015).   
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2.1.3 HUMAN LEUKOCYTE ANTIGEN (HLA) GENE REGION 
ASSOCIATES STRONGLY WITH TYPE 1 DIABETES 
Type 1 diabetes develops as a result of a complex interaction between genetic 
and environmental factors. Involvement of the genetic factors in the 
aetiology of type 1 diabetes is evidenced by clustering of the disease in 
families. Twin studies reveal that the proportion of the twin pairs with both 
of the twins affected by the disease is considerably higher among identical 
than non-identical twins acting as further proof of the genetic component in 
the disease aetiology (Hyttinen et al, 2003). By the age of 60, a majority 
(65%) of the initially healthy persons with an affected identical twin will 
develop the disease (Redondo et al, 2008).  
Approximately half of the genetic susceptibility is conferred by genes in 
the HLA gene region on chromosome 6 (Noble 2015). The relationship 
between the HLA gene region and type 1 diabetes has been known for 
decades (Nerup et al, 1974) and the HLA gene region is known to also 
associate with several other autoimmune diseases (Shiina et al, 2009). 
The HLA gene region is the most polymorphic region in the human 
genome with over 9000 HLA alleles now described (Noble, 2015; Robinson 
et al, 2013). Therefore, studying the HLA gene region, as well as interpreting 
the HLA genotyping results, can be challenging. Genes in the HLA region can 
be categorised into class I (HLA-A, -B and -C), class II (HLA-DR, -DQ and -
DP) and class III. HLA-A, -B and –C each consist of a single locus, HLA-DR 
consists of five loci (DRA, DRB1, DRB3, DRB4, DRB5) and HLA-DQ and 
HLA-DP of two loci (DQA1, DQB1, DPA1, DPB1) (Noble, 2015). Class III 
contains immunologically relevant genes, but does not encode the classical 
HLA antigens (Noble and Valdes, 2011). Some of the HLA alleles, for 
example alleles in the highly polymorphic HLA-B locus, bind similar peptides 
and can therefore be grouped into supertypes (Sidney et al, 2008).  
Several alleles in the HLA gene region are associated with either an 
increased or decreased risk for type 1 diabetes. HLA-DRB1 alleles DRB1*03 
and DRB1*04, and especially the genotype these alleles form together, create 
the strongest genetic risk for type 1 diabetes in Caucasians (Johnston et al, 
1983; Langholz et al, 1995; Pociot and Lernmark, 2016). As an example of the 
complexity of the HLA gene region, however, some of the DRB1*04 subtypes 
(there are a number of different subtypes of the DRB1*04 allele) are strongly 
associated with a decreased risk for type 1 diabetes (Harfouch-Hammoud et 
al, 1996). In Scandinavia, Europe and North America around 90-95% of the 
patients with type 1 diabetes carry a DRB1*03 or DRB1*04 allele or both (Dib 
and Gomes, 2009), but the proportion is decreasing along with an increasing 
disease incidence (Steck et al, 2011).   
Although the HLA class II alleles are mainly responsible for the genetic 
risk for type 1 diabetes within the HLA gene region, class I alleles also show 
association with the disease. For example, B*39 associates with an increased 
risk (Mikk et al, 2014), whereas B*57 with a decreased risk for type 1 diabetes 
(Noble et al, 2010).  
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The main function of the HLA gene region in the immune system is to 
protect the body from harmful agents. The HLA antigens recognise the 
foreign agents, bind the antigenic peptides and present them to T cells 
(Shiina et al, 2009; Noble and Valdes 2011). The disease associations of the 
HLA gene region are often interpreted to be a result of differences in the 
repertoire of self-peptides that are presented to T-cells (Tsai and Santamaria, 
2013). Only in a few autoimmune diseases, however, the genetic 
susceptibility is conferred solely to the HLA gene region (Howell 2013; Shiina 
et al, 2009).  
The remaining genetic risk for type 1 diabetes outside the HLA gene 
region is conferred by over 50 susceptibility loci that have been identified 
thus far (Onengut-Gumuscu et al, 2015; Pociot and Lernmark, 2016).  
 
 
2.1.4 PREVENTION OF TYPE 1 DIABETES IS STILL NOT POSSIBLE 
The ultimate goal of type 1 diabetes research is to find means to delay, 
prevent or reverse the disease process. A pre-clinical phase that can last from 
months to decades and that is characterised by the appearance of 
autoantibodies, precedes type 1 diabetes diagnosis (Knip et al, 2010). 
Primary prevention aims to prevent the initiation of the disease process by 
preventing the first appearance of the autoantibodies. Secondary prevention 
aims to prevent the development of the actual clinical disease after 
autoantibody detection. Tertiary prevention aims to preserve at least a part of 
the insulin-producing capacity of the ?-cells after the disease diagnosis.  
There are several ongoing type 1 diabetes prevention trials (Jacobsen et al, 
2016), but means to prevent or delay the clinical onset of type 1 diabetes have 
thus far not been found. These trials have nevertheless revealed new 
information regarding the pre-clinical phase of type 1 diabetes. The 
pre-clinical phase starts when the autoantibodies to pancreatic islet antigens 
are detectable. Autoantibodies to insulin, glutamic acid decarboxylase, 
insulinoma-associated antigen 2 and zinc transporter-8 are usually measured 
to investigate the risk for type 1 diabetes or the pre-clinical disease status 
(Ziegler et al, 2013). The risk for clinical disease is estimated as 
approximately 10-15% (during 5-10 years) with a single autoantibody and 
35-70 % (during 5-10 years) with multiple autoantibodies (Steck et al, 2015; 
Ziegler et al, 2013). The pre-clinical phase may also be characterised by a 
weaker insulin response years before the diagnosis, suggesting a decrease in 
?-cell function or in ?-cell mass (Koskinen et al, 2016).  
Discussion is ongoing as to whether all children or children with close 
relatives with type 1 diabetes should be screened for autoantibodies or for a 
weakened insulin response (Insel et al, 2015; Ziegler et al, 2016). It has been 
proposed that the asymptomatic autoantibody-positive children should be 
diagnosed as 'Autoimmune ? Cell Disorder' patients, because such a large 
percentage of autoantibody-positive children do develop the clinical disease 
over time (Bonifacio et al, 2017). According to this view introducing a 
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diagnosis to these asymptomatic children will over time change the future 
scope from the treatment of type 1 diabetes to the treatment and prevention 
of pre-clinical diabetes (Bonifacio et al, 2017), as well as reduce the 
prevalence of ketoacidosis (consequence of the body using fat as an energy 
source instead sugar due to lack of insulin) at diagnosis of clinical type 1 
diabetes (Ziegler et al, 2016). This view has been criticised on basis that not 
all children with autoantibodies develop type 1 diabetes, or the development 
may take as long as 20 years (Knip et al, 2010). A concern is that labeling 
these children as patients may cause psychological stress for the children and 
their parents (Knip et al, 2017), since mothers who are aware of their 
children´s genetically increased risk for type 1 diabetes, experience more 
anxiety (Roth et al, 2015). It has also been recently shown that reversion of ?-
cell autoimmunity (autoantibodies that have persistently been detected 
disappear) is possible, highlighting the fact that not all children with 
autoantibodies will develop type 1 diabetes, although the reversion is strongly 
restricted to children with a single autoantibody (Vehik et al, 2016).  
According to the ”Barker Hypothesis”, also referred to as the ”Foetal 
Origin Hypothesis” diseases occurring in different stages of life may have 
their origin in the foetal or neonatal environment (Barker and Osmond, 
1986). While this hypothesis was originally proposed in relation to diseases 
occurring in later life, the idea of a foetal origin and an early programming of 
type 1 diabetes have been suggested by many investigators based on the 
appearance of type 1 diabetes related autoantibodies sometimes only months 
after birth (Siljander et al, 2009). The development of both the foetal 
immune system and the pancreas begin during the first weeks of pregnancy, 
and by 7.5 weeks, insulin-positive cells can be detected in the foetal pancreas 
(Holt and Jones, 2000; Piper et al, 2004). Mother or pregnancy-related 
factors may modify this development and may therefore prove to be 
important in early programming of type 1 diabetes. First study in which 
pregnancy-related environmental factors will be monitored and that aims for 
prevention of type 1 diabetes is now being carried out in Australia (Penno et 
al, 2013) with no reported results yet. In this study for example the gut 
microbiota, nutritional status and weight gain of the mother during 
pregnancy will be analysed. 
While waiting for successful means of preventing the disease, advances 
are taking place in the management of an already diagnosed disease. The 
results of pancreas and islet cell transplantation have improved with 
advances in surgical techniques and immunosuppression (Niclauss et al, 
2016). For example, in Norway, 44% of the patients showed a 50% reduction 
in insulin requirement 4 years after the initial islet transplantation (Schive et 
al, 2017). The emerging technologies will also provide some advances for the 
patients to monitor their disease. For example, with the help of continuous 
blood sugar monitoring and insulin/glucagon pumps controlled via a 
smartphone (the first artificial pancreas which has been approved by the 
FDA in 2016), the prevention or hypo- and hyperglycemias will become 
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considerably easier. This is highly important, since the life expectancy has 
been estimated to be over 10 years shorter in type 1 diabetic patients even in 
the western world (Livingstone et al, 2015). In Finland, for example, no clear 
advances have occurred during the last decades in the treatment balance of 
patients with type 1 diabetes (Valle et al, 2010).  
 
 
2.2 VITAMIN D 
 
Vitamin D has been studied during the past decades with an unseen intensity 
with a PubMed search now producing 58 847 hits for the term “vitamin D”. 
Vitamin D has been suggested as a wonder cure for practically every illness 
and undesired health condition producing even greater hype than 
antioxidants in the 1990s. Practically all chronic diseases have shown 
associations with low serum 25OHD concentrations, but the researchers have 
not been able to define the significance of these various associations let alone 
to translate this information into clinical practice.  
 
2.2.1 VITAMIN D RESEMBLES A HORMONE 
Vitamin D is obtained mainly from the UV light through skin, and to a lesser 
extent from the diet, where the most important sources are fish and at least 
in Finland, fortified foods such as milk and margarine. Although it is called a 
vitamin, the actions of vitamin D in the body resemble that of steroid 
hormones and in contrast to the traditional definition of a vitamin, it can also 
be produced in the body. Chemically vitamin D refers to a group of 
fat-soluble secosteroids. In humans, the most important compounds in this 
group are vitamin D3 (also known as cholecalciferol) and vitamin D2 
(ergocalciferol). 
Vitamin D is necessary for normal calcium and phosphate metabolism by 
stimulating the absorption of these minerals from the intestine. In the 
absence of adequate vitamin D supply, the risk for developing rickets 
(defective mineralisation of the bones) in children and osteomalasia 
(softening of the bones) in adults increases.  
In Finland, the archiatre Arvo Ylppö already paid attention in 1920s to the 
high incidence of rickets that he described to be a result of the northern 
location and low amount of sunlight (Ylppö, 1925). This eventually led to a 
regular vitamin D supplementation of 100 ?g per day for the infants in 
Finland, which was gradually decreased to the current recommendation of 10 
?g per day (www.thl.fi).  
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2.2.2 SEVERAL GENES ARE INVOLVED IN VITAMIN D METABOLISM  
Vitamin D synthesis in the body begins in the skin as a result of exposure to 
UV radiation. In the skin, UV radiation promotes the formation of 
previtamin D from 7-dehydrocholesterol that is derived from cholesterol 
(Prabhu et al, 2016). The production of previtamin D in the skin is dependent 
by the amount of pigmentation (Xiang et al, 2015). Exposure to UV radiation 
increases the pigmentation in the skin decreasing previtamin D synthesis in 
the skin.  
NAD synthetase 1 (NADSYN1) and 7-dehydrocholesterol reductase 
(DHCR7) convert 7-dehydrocholesterol back to cholesterol thus being able to 
control the amount of available 7-dehydrocholesterol for the previtamin D 
synthesis (Prabhu et al, 2014). NADSYN1 and DHCR7 genes are located near 
each other and are often referred to as the NADSYN1/DHCR7 locus.   
Previtamin D is converted by non-enzymatic thermal isomerisation to 
vitamin D (Bouillon et al, 1998). Vitamin D is converted in the liver to 
25OHD by cytochromes P450 (CYPs) enzymes, encoded by the CYP2R1 and 
CYP27A1 genes (Schuster, 2011). 25OHD is then transported in the 
circulation by vitamin D binding protein (DBP), encoded by the group-
specific component (GC) gene.  
Cubilin, encoded by the CUBN gene, mediates the uptake of the 25OHD-
DBP complex to the kidney (Christensen et al, 2013; Nykjaer et al, 2001). 
25OHD is hydroxylated to the metabolically active form of vitamin D, 
1,25OHD, by 1-?-hydroxylase encoded by the CYP27B1 gene mainly in the 
kidney, but also, for example, in the ?-cells and immune cells (Bikle, 2009).  
Degradation of active vitamin D is initiated by a hydroxylase encoded by the 
CYP24A1 gene (Bikle, 2011). 
The active form of vitamin D acts in the body through the vitamin D 
receptor (VDR), encoded by the VDR gene (Brown et al, 1999; Issa et al, 
1998). VDR is a nuclear transcription factor that belongs to the nuclear 
hormone receptor superfamily and regulates the transcription of vitamin D 
target genes (Bouillon et al 1998; Issa et al, 1998). After the VDR is activated 
via binding the active vitamin D, it heterodimerizes with other nuclear 
receptors and binds to specific DNA sequences, referred to as vitamin D 
response elements (VDREs) in the promoter region of vitamin D target genes 
(Saccone et al, 2015).  
VDRs are found in almost all tissues in the human body and they regulate 
the expression of hundreds of genes. VDR gene polymorphisms are 
associated with type 1 diabetes and other autoimmune diseases, different 
cancers, severe diabetic retinopathy, and osteoporosis, but also for example 
with pancreatic insulin secretion (Hitman et al, 1998; Jolliffe et al, 2016; 
Ogunkolade et al, 2002; Pani et al, 2000). 
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2.2.3 VITAMIN D DEFICIENCY IS DEFINED BY SERUM 25OHD 
CONCENTRATION  
Concentration of 1,25OHD in the blood is efficiently regulated while 25OHD 
concentration is not. Serum 25OHD concentration therefore provides an 
indication of vitamin D stores obtained from both synthesis in the skin and 
dietary intake and is generally accepted as an indicator of vitamin D status in 
the body (Zerwekh et al, 2004). Although vitamin D can be produced in the 
skin through UV radiation, it is usually essential for people living far from the 
equator to receive vitamin D from diet and supplements. 
Vitamin D status is also modified by several physiological, life-style and 
genetic factors. Factors that associate with low serum 25OHD concentration 
include decreased intestinal absorption and for example smoking, low 
physical activity and high body mass index (BMI) (Margulies et al, 2015; 
Miettinen et al, 2014; Skaaby et al, 2016). The biological mechanisms 
explaining most of these associations are poorly understood.  
The heritability of serum 25OHD concentration is estimated to be at least 
30% (Hunter et al, 2001; Shea et al, 2009). Several single nucleotide 
polymorphisms (SNPs) in genes of the metabolic pathway of vitamin D affect 
serum 25OHD concentration. Previous studies have consistently found 
associations between serum 25OHD concentration and several SNPs in the 
NADSYN1/DHCR7, CYP2R1, CYP24A1 and GC genes or near these genes 
(Abbas et al, 2008; Ahn et al, 2010; Engelman et al, 2008; Fang et al, 2009; 
Jolliffe et al, 2016; McGrath et al, 2010; Wang et al, 2010). SNPs located in 
the VDR and GC genes influence the response to vitamin D supplementation 
(Gaffney et al, 2016).   
Frequently discussed matters in the field of vitamin D research are the 
optimal serum 25OHD concentration for health, as well as the threshold for 
vitamin D deficiency.  
For a long time, serum 25OHD concentration of ?25 nmol/l was 
considered indicative of vitamin D deficiency. With the increase of research 
in this field in the 1990s revealing a number of associations between vitamin 
D and different diseases, many researchers started to question whether the 
threshold should be set higher. The Institute of Medicine has in their report 
(2011) concluded that 50 nmol/l or higher should cover the vitamin D 
requirements of 97.5% of the population in North America, whereas the 
Endocrine Society ended up recommending a serum 25OHD concentration 
of at least 75 nmol/l as sufficient (Holick et al, 2011). This debate has been 
ongoing in Finland as well with some researchers stating that the 
recommendations should be set higher (Mäkitie, 2012) and some speculating 
that the current recommendations may be adequate (Raulio et al, 2016).  
It has been argued that the threshold for an adequate vitamin D status 
should not be set based on the lowest serum 25OHD concentration that 
prevents symptoms of vitamin D deficiency (such as rickets or osteomalasia), 
but based on different criteria. For example, it has been suggested that 
vitamin D status should be equal to that of people living near the equator 
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(>100 nmol/l) with living habits similar to our ancestors (Luxwolda et al, 
2012). It has also been suggested that vitamin D intake should be high 
enough for a lactating mother to be able to fulfil the vitamin D need of the 
infant which has been estimated to end up with similar range around 
100-150 nmol/l (Heaney, 2014).   
Researchers do not agree on the question of toxicity of vitamin D either. 
The current tolerable upper limit of vitamin D intake is according to the 
European Food Safety Authority 25 ?g per day for children under 10 and 
50 ?g for older children and adults (www.efsa.europa.eu). The Institute of 
Medicine in the United States suggests a maximum of 25 ?g per day for ages 
0-1, 62.5 ?g for ages 1-3, 75 ?g for ages 3-8 and 100 ?g for age 9 and above 
(IOM, 2011). The Encocrine Society recommends a maximum of 400 ?g per 
day (Holick et al, 2011; Ross et al, 2011). A threshold for toxic serum 25OHD 
concentration has been suggested to lie somewhere from 250 to 600 nmol/l, 
depending on the view (Hathcock, 2007; Holick et al, 2011; Jones 2008).  
In Finland, vitamin D deficiency has shown to be common during the past 
decades in different population groups such as children and adolescents, 
pregnant women, dark-skinned immigrants and in the general adult 
population (Cashman et al, 2016; Islam et al, 2012; Miettinen et al, 2014; 
Munger et al, 2013; Pekkinen et al, 2012). Therefore, nutrition policy 
strategies have been implemented to improve general vitamin D status in 
Finland. Vitamin D fortification was started in 2002 with an amount of 0.5 
?g of vitamin D per 100 ml of liquid dairy products and 10 ?g per 100g of 
margarine (Ministry of Trade and Industry of Finland, 2002). In 2010 the 
suggested amount of fortification was doubled (National Nutrition Council, 
2010). According to national population-based FINRISK surveys 
implemented in Finland in 2002, 2007 and 2012, the average vitamin D 
intake has increased from 2002 to 2012 (Raulio et al, 2012), although the 
increase results not only from an increased vitamin D intake from dietary 
sources, but also from increased use of vitamin D containing supplements.  
 
 
2.2.4 VITAMIN D ASSOCIATES WITH SEVERAL DISEASES  
In addition to direct proven consequences of vitamin D deficiency, rickets in 
children and osteomalasia in adults, inadequate vitamin D status is 
associated with a large number of diseases including different types of 
cancers, cardiovascular and autoimmune diseases. Vitamin D status 
associates also with the survival of some of these diseases. The inability to 
define the significance of these associations together with mainly lean results 
in intervention trials has led to a suggestion that poor vitamin D status is a 
mere biological marker of ill health rather than a causal agent in the disease 
process of any of these diseases (Autier et al, 2014).  
Some relatively strong evidence of the capacity of vitamin D to control 
symptoms of a disease, however, exists. Additional vitamin D 
supplementation decreases the occurrence of severe asthma attacks in 
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children according to a recent Cochrane review of clinical trials (Martineau, 
2016). In a recent randomised control trial it was also shown that the 
symptoms of children with autism spectrum disorder can be efficiently 
controlled with additional relatively high dose of vitamin D supplementation 
(7.5 ?g/kg/day) (Saad et al, 2016).  
It may be that the amount of vitamin D supplementation in most of the 
previous intervention trials has been too low to produce notable differences 
in vitamin D status between the treated and untreated groups, and therefore 
no protective effect has be seen.  
 
 
 
 
2.3 EXISTING EVIDENCE ON THE RELATIONSHIP 
BETWEEN VITAMIN D AND TYPE 1 DIABETES 
 
 
High-quality intervention trials investigating the capacity of vitamin D to 
prevent or delay type 1 diabetes are lacking, but there is a considerable 
amount of studies evaluating epidemiological associations.  
 
2.3.1 GEOGRAPHICAL AND SEASONAL PATTERNS OF TYPE 1 
DIABETES  
The involvement of vitamin D in the pathogenesis of type 1 diabetes has been 
suggested based on an epidemiological association between geographical 
location and incidence of type 1 diabetes. Type 1 diabetes is more common in 
the northern latitudes (EURODIAB ACE Study Group, 2000; Dahlquist and 
Mustonen, 1994) which has been suggested to reflect the effect of a low 
supply of vitamin D through UV radiation. It has also been shown that the 
average daily UV radiation predicts the future incidence of type 1 diabetes 
(Sloka et al, 2008). There seems to be an overall higher disease incidence in 
countries with a western life-style, however, compared to lower income 
countries at the same latitude, for example between the Western and Eastern 
Europe or between Finland and Russia (EURODIAB ACE Study Group, 
2000; Podar et al, 2001; Kondrashova et al, 2005). In Sardinia, the disease 
incidence is considerably higher compared to the other parts of Italy and 
southern Europe (Borchers et al, 2010a). Given the high amount of solar UV 
radiation in Sardinia (~300 days of sunlight per year) (Cocco et al, 2012), the 
high incidence of type 1 diabetes is inconsistent with the UV radiation 
hypothesis. Genetic factors have been suggested to at least partly explain the 
high incidence (Borchers et al, 2010a).  
The supply of vitamin D through skin exposure to UV radiation has also 
been suggested to influence the clinical diagnosis of type 1 diabetes. A 
seasonal pattern in the clinical diagnosis of type 1 diabetes was presented in a 
study that used comprehensive data of the World Diabetes Mondiale project 
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(WHO DiaMond) collected from 53 countries worldwide (Moltchanova et al, 
2009). Altogether 42 of the 105 centers included showed significant seasonal 
variation. The peak in the season of diagnosis varied according to the 
geographical position with steeper seasonal pattern detected in areas further 
from the equator. Mainly a peak in the season of diagnosis was detected 
during the winter months and a trough during the summer months. A 
seasonal trend in the disease diagnosis has been presented in other studies as 
well, but with the peak found during different seasons in different studies 
(Karvonen et al, 1996; Samuelsson et al, 2007; Vaiserman et al, 2007).  
Some studies have also demonstrated seasonality in birth of type 1 
diabetes patients suggesting an in-utero effect of a seasonal environmental 
factor. A peak in the season of birth of type 1 diabetes patients has been seen 
during the spring and summer months in some studies (Kahn et al, 2009; 
Rothwell et al, 1996), whereas other studies report no seasonal trends 
(McKinney and the EURODIAB Seasonality of Birth Group, 2001).  
While the geographical and seasonal patterns associated with type 1 
diabetes have been interpreted to result from differences in the supply of 
vitamin D, it needs to be considered that in addition to vitamin D synthesis, 
UV radiation has a variety of other functions in the human body. It is not 
known whether the other effects of UV radiation contribute in the 
pathogenesis of type 1 diabetes. Since viral infections are also suspected 
environmental triggers of type 1 diabetes, the known seasonal trend in viral 
infections may explain the seasonal trends in type 1 diabetes (Afoke et al, 
1991). The seasonal trends in viral infections have been suggested to result at 
least partly from seasonal variation in UV radiation and thus vitamin D 
supply (Abhimanyu and Coussens, 2017).  
Since the autoimmune process of type 1 diabetes is known to begin years 
or even decades before the diagnosis (Knip et al, 2010), the detected seasonal 
pattern in the clinical onset of the disease does not provide information on 
the environmental triggers that initially start the autoimmune process. It has 
been discovered though, that also the appearance of the first autoantibodies 
follows a seasonal pattern with higher appearance of the first autoantibodies 
during the fall and winter (Kimpimäki et al, 2001; Lynch et al, 2008). 
Interestingly, it has also been shown that gene expression follows a 
seasonal pattern. This novel finding was presented in 2015 with results of a 
seasonal pattern in mRNA expression levels of more than 4000 genes 
(Dopico et al, 2015). Importantly, many of these genes encode proteins 
essential for the function of the immune system, such as interleukin 6 
receptor and C-reactive protein. In winter a pro-inflammatory transcriptomic 
profile can be detected, which may be a consequence of the lack of sunlight 
(Dopico et al, 2015). These findings create a novel approach in understanding 
the meaning of the observed seasonal patterns in type 1 diabetes and do not 
support a theory that the mere restricted supply of vitamin D would explain 
the findings. 
 
 29 
 
2.3.2 STUDIES IN THE NON-OBESE DIABETIC (NOD) MICE  
Non-obese diabetic (NOD) mice provide a useful tool for investigating the 
role of vitamin D and other environmental factors in the aetiology of type 1 
diabetes. NOD mice develop autoimmune diabetes as a result of T-cell 
mediated destruction of the ?-cells in the pancreas usually by 4-6 months of 
age (Delovitch and Singh, 1997).  
It was already shown in the 1990s that treating the NOD mice before the 
first symptoms of an inflammation in the ?-cells with 1,25OHD, delays the 
disease process (Mathieu et al, 1992). In these early experiments, a vitamin D 
analogue (KH1060) was also shown to decrease the incidence of type 1 
diabetes in NOD mice (Mathieu et al, 1995). Later in the 2000s it was shown 
that the active form of vitamin D not only delays the disease process but can 
even completely protect the NOD mice from the disease (Zella et al, 2003). 
The effect of vitamin D during the pre-clinical phase has also been 
studied. First it was shown that although a vitamin D analogue (MC1288) 
alone could not delay the disease process in the pre-clinical phase of NOD 
mice, the combination of vitamin D and and cyclosporin A 
(immunosuppressive drug that inhibits signalling from the T-cell receptor) 
could (Casteels et al, 1998). Later it was shown that another vitamin D 
analogue (Ro 26-2198) was independently capable of delaying the disease 
process in the pre-clinical phase of the disease NOD mice (Gregori et al, 
2002).  
Since different vitamin D analogues can delay or prevent diabetes 
progression in NOD mice, it was a surprise to find that in the NOD mice 
genetically lacking the VDR, the disease development did not differ from the 
control NOD mice (Gysemans et al, 2008). Another later study, however, 
showed an accelerated type 1 diabetes development in NOD mice lacking the 
VDR, but interestingly, this acceleration was only seen when the mice were 
calcium deficient (Drivel et al, 2011). Feeding the mice with a diet high in 
calcium prevented the accelerated disease process (Driver et al, 2011). 
The challenge in these experiments or in testing the effect of these vitamin 
D analogues in humans is the fact that the positive results have been 
obtained by using non-physiological vitamin D analogue dosing that leads to 
increased calcium levels. These studies do, however, provide strong evidence 
of the capacity of vitamin D analogues to interfere with the disease process in 
the NOD mice and therefore justify future intervention studies in humans. 
 
 
2.3.3 STUDIES IN HUMANS  
Several human studies have investigated the association between vitamin D 
intake or vitamin D status and type 1 diabetes. Overall the results are 
conflicting and well-planned large intervention trials are still missing. 
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Intake of vitamin D during pregnancy and childhood  
Studies evaluating the relationship between type 1 diabetes or autoantibody 
appearance and intake of vitamin D from dietary sources or supplements 
during pregnancy or childhood will be described in this section. Three 
different approaches have been used in these studies, intake of vitamin D 
from cod-liver oil, from vitamin D containing supplements or from food.  
Vitamin D status is influenced by many factors: the amount of UV 
radiation exposure, diet, intestinal absorption, life-style and genetic factors. 
Several factors such as sex, baseline vitamin D status and physical activity 
have also shown to modify the individual response for vitamin D 
supplementation (Rees et al, 2016). Therefore, studies that have evaluated 
the association between type 1 diabetes and vitamin D intake based only on 
the vitamin D supply from dietary sources or supplements, cannot reliably 
define the actual vitamin D status of the mother or infant. This needs to be 
considered when evaluating the following evidence.   
In the first study in the field, it was shown that maternal cod-liver oil 
supplementation associated with a lower risk for type 1 diabetes in the 
offspring in Norway (Stene et al, 2000). The same group, however, could not 
confirm their findings in a larger study with a similar study setting (Stene et 
al, 2003). The maternal use of vitamin D supplements associated with a 
reduced occurrence of autoantibodies in the All Babies In Southeast Sweden 
(ABIS) study at 1 year of age, but not at 2.5 (Brekke et al, 2007). Later, the 
ABIS study did not find an association between maternal intake of vitamin D 
supplements and the risk for type 1 diabetes in children before 14-16 
(Granfors et al, 2016). No association was found between maternal vitamin D 
supplement use and the risk for type 1 diabetes or the occurrence of 
autoantibodies in Finnish children (Marjamäki et al, 2010). Higher maternal 
vitamin D intake from food, but not from supplements, associated with a 
decreased risk for the appearance of autoantibodies in the United States 
(Fronczak et al, 2003). The authors suggest that this may result, for example, 
from a better bioavailability of vitamin D from food than from supplements.  
Vitamin D supplement use during infancy associated with a considerable 
reduction in type 1 diabetes risk in Finland (Hyppönen et al, 2001). The 
children that regularly received vitamin D supplementation had a markedly 
(88%) reduced risk for developing type 1 diabetes. The same association was 
shown with data from seven European countries (The EURODIAB Substudy 
2 Study Group, 1999). In Norway, no association was found between 
cod-liver oil or vitamin D supplementation during infancy with the risk for 
type 1 diabetes in a pilot study, but in a larger study by the same group a 
couple of years later, the use of cod-liver oil, but not vitamin D supplements, 
during infancy associated with a reduced risk for type 1 diabetes (Stene et al, 
2000; Stene et al, 2003). The intake of vitamin D prior to diagnosis did not 
associate with the appearance of autoantibodies or the risk for developing 
type 1 diabetes in the United States (Brekke et al, 2007; Simpson et al, 2011).  
 31 
Overall these studies present conflicting results. This may be a result of a 
low vitamin D supplementation recommendation amount, leading to only 
small differences in the actual vitamin D status of the mothers/infants that 
took vitamin D supplementation compared to those that did not. An evident 
exception is the Finnish study by Hyppönen et al (2001) where a daily dose of 
50 ?g of vitamin D supplementation was recommended for the infants 
leading presumably to a marked difference in vitamin D status between the 
supplement users and non-users. This study showed the strongest 
association between intake of vitamin D and type 1 diabetes risk of all studies 
reported thus far. 
 
Serum 25OHD concentration during pregnancy and childhood  
Studies evaluating the relationship between type 1 diabetes and serum 
25OHD concentration during pregnancy or childhood will be described in 
this section.  
Low serum 25OHD concentration during the last trimester of pregnancy 
associated with an increased risk for type 1 diabetes in the child in Norway 
(Sørensen et al, 2012). In a relatively large Danish and small Italian study no 
association was found between neonatal serum 25OHD concentration in 
dried blood spots and risk for developing type 1 diabetes (Cadario et al, 2015; 
Jabobsen et al, 2016). In Norway, the average serum 25OHD concentrations 
were considerably higher than in the Danish study, although they cannot be 
directly compared because of the differences in both analytical methods and 
sample collection. 
Serum 25OHD concentrations in children prior to diagnosis did not 
associate with the appearance of autoantibodies or the development of type 1 
diabetes in the Finnish DIPP and DIABIMMUNE studies, and in the DAISY 
study in the United States (Mäkinen et al, 2016; Reinert-Hartwall et al, 2014; 
Simpson et al, 2011). In a German study, however, children with multiple 
autoantibodies were found to have lower serum 25OHD levels than children 
with no autoantibodies (Raab, 2014). In this study vitamin D deficiency was 
not, however, associated with faster development of type 1 diabetes in 
children with multiple autoantibodies. Another study that used samples 
collected from the military service members in the United States found that 
lower serum 25OHD concentration associated with an increased risk for 
developing type 1 diabetes (Gorham et al, 2012). 
 
Serum 25OHD concentration among type 1 diabetic patients 
There seems to be no information available on the possible differences in 
vitamin D intake between type 1 diabetic patients and controls, but it has 
been shown that type 1 diabetic patients have lower serum 25OHD 
concentrations than non-diabetic controls (Littorin et al, 2006; Pozzilli et al, 
2006). Given the substantial evidence on lower serum 25OHD 
concentrations compared to controls in various autoimmune and other 
chronic diseases, and considering the inability of the current research to 
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interpret these associations, the clinical significance of these observations 
remains unclear.  
The low serum 25OHD concentrations in type 1 diabetic patients may be 
explained by the presence of conditions that have an impact on vitamin D 
metabolism/ supply. Celiac disease is more common among type 1 diabetic 
patients than in non-diabetic controls; the prevalence of celiac disease is 
about 1% in the general population but higher (1-16%) in type 1 diabetic 
patients (Pham-Short et al, 2015). Poorer vitamin D status may therefore 
result at least partly from decreased intestinal absorption of vitamin D 
among the patients. Chronic kidney disease, as well as autoimmune thyroid 
disease, both affect up to 30% of type 1 diabetic patients (González et al, 
2004; Hovind et al, 2003). Both of these conditions associate strongly with 
vitamin D deficiency, but the detailed mechanism explaining the association 
is not known.  
In addition to the classical long-term complications related with type 1 
diabetes, such as retinopathy, neuropathy and increased cardiovascular 
disease risk, the disease also relates with skeletal fragility (Weber and 
Schwartz, 2016). While it has been suggested that hyperglycemia may be the 
explaining factor (Neumann et al, 2011), the role of vitamin D has also been 
discussed due to its central role in the development and maintenance of 
healthy bones (Thrailkill and Fowlkes, 2013). The ability of the disease 
process of type 1 diabetes to alter vitamin D metabolism is not known. The 
increased fracture risk of the type 1 diabetic patients, however, seems 
interestingly to already be apparent during early stage of the disease (Weber 
et al, 2015). This raises a question whether there are certain vitamin D 
metabolism related innate differences in type 1 diabetic patients compared to 
controls, which may affect not only the formation of the bones but possibly 
also the risk for type 1 diabetes.  
It has been reported that people with an immune-mediated disease such 
as multiple sclerosis, have a weaker response to vitamin D supplementation 
(Bhargava et al, 2016). This suggests that the activation of the immune 
system that follows the onset of an immune-mediated disease increases the 
need for active vitamin D, mirrored by a decrease in serum 25OHD 
concentration. It is also possible, though, that the low serum 25OHD 
concentrations of the patients with type 1 diabetes or other immune-
mediated disease are at least partly explained by a decreased intestinal 
absorption of vitamin D. 
Intervention studies investigating the effects of vitamin D 
supplementation on type 1 diabetic patients are scarce. In one study 
supplementation with active vitamin D did not show protective effect on the 
remaining ?-cells of the patients (Bizzarri et al, 2010). However, a relatively 
large amount of vitamin D supplementation (100 ?g per day) was in another 
study shown to improve the blood sugar control of type 1 diabetic patients 
(Bogdanou et al, 2016). The effect of relatively large amount of vitamin D 
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supplementation during pre-clinical phase of the disease should be 
investigated. 
 
 
2.3.4 GENETIC FACTORS IN THE METABOLIC PATHWAY OF VITAMIN 
D 
Several genes, or SNPs, in the metabolic pathway of vitamin D have been 
associated with type 1 diabetes.  
The most studied SNPs are Taq1 (rs731236), Bsm1 (rs154410), Apa1 
(rs7975232) and Fok1 (rs2228570) located in the VDR gene. These SNPs 
have also been associated with other autoimmune diseases and osteoporosis. 
The VDR gene encompasses at least 105 kb and the polymorphisms in this 
large gene have not been extensively studied. In Caucasians, there are five 
genomic blocks within the VDR gene showing high linkage disequilibrium 
(Fang et al, 2005). Within such a block, SNPs are in strong linkage 
disequilibrium with each other, but show very little linkage disequilibrium 
with SNPs outside the block.  
A systematic review and meta-analysis published in 2014 concluded that 
there is no association between the individual SNPs in the VDR gene (Taq1, 
Bsm1, Apa1 and Fok1) and type 1 diabetes, whereas the haplotypes that some 
of these SNPs form together were suggested to associate with the disease 
(Tizaoui et al, 2014). Another meta-analysis from 2012 found an association 
between type 1 diabetes and Bsm1 but not with Taq1, Apa1 and Fok1 (Zhang 
et al, 2012). When exploring the existing evidence in more detail, it was seen 
that some studies report clearly different results for the Bsm1 and Taq1 SNPs 
(please see for example Panierakis et al, 2009), whereas others report almost 
equal associations for these two SNPs (please see for example Orlow et al, 
2012). 
Looking at this inconsistency a little bit closer, it was noticed that there 
are two mutations (SNPs) located in the binding site of the Bsm1 primer that 
has been extensively used in studies using traditional restriction fragment 
length polymorphism technique (Figure 2). As it turned out, the 
inconsistency in the results had been noticed by others as well. Zajícková et 
al. (2003) experimentally tested the effect of SNPs in the Bsm1 primer 
binding site. They found that SNP in the Bsm1 primer binding site can cause 
failure of the polymerase chain reaction (PCR) amplification with a drop-out 
of the b allele in heterozygotes, and result in errors in the prevalence of BB 
genotypes of the Bsm1 SNP. This may lead to errors in the results and 
confound genetic findings.  
Therefore, the results of a considerable amount of previous studies 
assessing the association between VDR gene polymorphisms and type 1 
diabetes may contain errors and should be evaluated with caution. When 
using primers that do not overlap with the SNPs in the VDR gene sequence 
(Orlow et al, 2012; Figure 2), the Bsm1 and Taq1 SNPs produce similar 
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associations and can be concluded to be in almost complete linkage 
disequilibrium.  
 
 
 
 
Figure 2. Location of the single nucleotide polymorphisms (SNPs) in the vitamin D receptor 
(VDR) gene sequence. Two SNPs (5 and 6) are located in the binding site of the PCR primer 
often used in studies using restriction fragment length polymorphism technique. 
 
 
 
ccttcaccatggacgacatgtcctggacctgtggcaaccaagactacaagtaccgcgtca 
gtgacgtgaccaaaggtatgcctagactccacctcctggggagtctttttcagctcccag 
attctggctccacccgtcctggggtttggctccaatcagatacatgggagggagttaggc 
accaacagggagagaagggcgagggtcagacccatggggttggaggtgggtgggcggctc 
ctcagctctgcccgcagtacctggccattgtctctcacagccggacacagcctggagctg 
attgagcccctcatcaagttccaggtgggactgaagaagctgaacttgcatgaggaggag 
catgtcctgctcatggccatctgcatcgtctccccaggtatggggccaggcagggaggag 
ctcagggacctggggagcggggagtatgaaggacaaagacctgctgagggccagctgggc 
aacctgaagggagacgtagcaaaaggagacacagataaggaaatacctactttgctggtt 
tgcagagcccctgtggtgtgtggacgctgaggtgcccctcactgcccttagctctgcctt 
gcagagtgtgcaggcgattcgtaggggggattctgaggaactagataagcagggttcctg 
     1       2        3 
gggccacagacaggcctgcgcattcccaatactcaggctctgctcttgcgtgaactgggc 
                              4      
tcaacattcctgttatttgaggtttcttgcgggcagggtacaaaactttggagcctgaga 
                                                      5 
gatggttctgcctatatagtttacctgattgattttggaggcaatgtgcagtgacccttg 
        6      
acctcttccgctggttagaggtgagaagagggagaaaaggccgaagaggaagttattgtg 
 
1 = rs1544410 (Bsm1) 
2 = rs11574109 
3 = rs112473013 
4 = rs11574110 
5 = rs757343 
6 = rs11574111 
 
Bsm1 primers overlapping with two SNPs in the VDR gene sequence 
(used in several RFLP studies, for example by): 
 
caaccaagactacaagtaccgcgtcagtga BsmI PCR primer 1 
cccttgacctcttccgctggtt    BSM1 PCR primer 2   
Bsm1 primers not overlapping any SNPs in the VDR gene sequence 
(used for example by Orlow et al, 2011): 
 
cctcactgcccttagctctg  Bsm1 PCR primer 1 
ccacagacaggcc   Bsm1 PCR extension primer  
ctttggagcctgagagatgg  Bsm1 PCR primer 2 
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In a recent review covering over 50 gene loci currently known to contribute 
to the risk for type 1 diabetes (Pociot and Lernmark, 2016) only one SNP 
association was reported in the central genes in the metabolic pathway of 
vitamin D (rs4646536 in CYP27B1). This association was originally reported 
in 2007 by Bailey et al. and confirmed by the same group in a study in 2011. 
In the latter study an association was also found between the SNPs in the 
DHCR7 and CYP2R1 genes and type 1 diabetes (Cooper et al, 2011). 
Rs4646536 in the CYP27B1 gene has also been associated with type 1 
diabetes related autoantibodies along with rs12785878 in NADSYN1/DHCR7 
gene locus (Frederiksen et al, 2013a).  
The results of associations between type 1 diabetes and SNPs located in 
genes in the metabolic pathway of vitamin D have been partly conflicting. 
There are several explanations for the inconsistency between the results, 
including small sample size leading to lack of statistical power, and 
differences in allele frequencies between different populations. The SNP 
association may also only be a marker of a causal genetic association 
meaning, for example, that different populations may have different SNP 
markers for a specific causal genetic factor (Uitterlinden et al, 2004). Last, 
genetic association studies without a justified biological mechanism 
explaining the associations will also always produce false also positive 
results. 
 
 
 
 
2.4 SUGGESTED MECHANISMS EXPLAINING THE 
RELATIONSHIP BETWEEN VITAMIN D AND TYPE 1 
DIABETES 
 
 
The evidence of an association between vitamin D and type 1 diabetes is 
mainly epidemiological without detailed information on the possible 
mechanisms explaining the association. Some mechanisms have been 
proposed mainly related to the capacity of vitamin D to modulate the 
functions of the immune system. Autoimmune diseases are characterised by 
an inflammation, which is part of the complex reactions of the immune 
system aimed at removing a harmful substance. A properly working immune 
system protects the body against invading micro-organisms such as viruses 
and bacteria, by producing antibodies and lymphocytes. Type 1 diabetes 
develops as a result of activation of the immune system when the ?-cells in 
the pancreas are incorrectly recognised as foreign and destroyed.   
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Vitamin D affects type 1 diabetes or type 1 diabetes affects vitamin D 
metabolism? 
 
While the participation of vitamin D deficiency in the development of 
autoimmune and other immune-mediated diseases has been suggested for 
decades, it has not been discussed whether the disease process itself and the 
alterations the disease produces to the physiology of the patient, could 
modify vitamin D metabolism. An interesting finding pointing towards this 
interpretation is that type 1 diabetic patients already have an increased 
fracture risk early in the disease (Weber et al, 2015). Although hyperglycemia 
has been suggested to contribute to the bone fragility of the patients, at least 
in the long term, it is not likely to explain the increased fracture risk early in 
the disease. It may be that the disease process of type 1 diabetes begins very 
early, possibly during the foetal period, and then modifies the development 
of vitamin D metabolism. This may be mirrored by an increased fragility of 
the bones of the patients, but also by lower serum 25OHD concentrations.  
 
 
T helper cell cytokine profile 
 
T helper cells are classified as Th1, Th2 and Th17 cells based on their cytokine 
profile (Harrington et al, 2005). The disease process of type 1 diabetes has 
traditionally been described to include a decrease in Th2 cytokine production 
and an increase in type Th1 cytokine production. Vitamin D, or its analogues, 
have been shown to decrease the Th1-associated pro-inflammatory cytokine 
production such as interleukin 2 and interferon-?, and to increase the 
Th2-associated anti-inflammatory cytokine production such as interleukin 5 
and interleukin 10 (Alhassan Mohammed et al, 2016; Boonstra et al, 2001; 
Lemire et al, 1995). 
Interestingly, the risk for developing an autoimmune disease or the risk 
for relapses of an existing autoimmune disease in women has been shown to 
be higher during the months following a delivery (Khashan et al, 2013; 
Vukusic et al, 2004). This has been interpreted to result from the presence of 
foetal cells in the circulation of the mothers postpartum, as foetal cells could 
induce a rejection reaction in the mother and therefore activation of the 
immune system (Borchers et al, 2010b). No consensus on the mechanism has 
been obtained though. The immune system encounters several changes 
during pregnancy to prevent the mother´s body from rejecting the 
developing foetus. Pregnancy is characterised by a decrease in Th1 cytokine 
production and an increase in Th2 cytokine production (Strom et al, 1996), 
following a shift back after the delivery. Serum 25OHD concentrations have 
been shown to strongly decrease after the delivery, which has been 
interpreted by the returning of the vitamin D status back to normal after 
pregnancy (Luxwolda et al, 2012). The same kind of an immediate drop in 
serum 25OHD concentrations has, however, also been shown after knee 
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surgery (Reid et al, 2011) which does not support this interpretation. It can 
be proposed that a shift from a Th2 to a Th1 pattern that is normal right after 
delivery together with a drop in serum 25OHD concentrations (increasing 
this shift) may be the triggering factor for genetically susceptible individuals 
for an initiation or worsening of an autoimmune disease.   
It has been discovered that also Th17 cells are important in the 
pathogenesis of type 1 diabetes evidenced by an increased production of Th17 
cells in correlation with an infection of the ?-cells in NOD mice 
(Martin-Orozco et al, 2009). The active form of vitamin D has been shown to 
decrease the production of Th17-associated pro-inflammatory cytokines (da 
Costa et al, 2016), therefore possibly participating in the initiation of the 
disease process of type 1 diabetes. 
 
 
Vitamin activating enzymes and VDRs in the cells of the immune system 
 
Immune cells have been shown to express vitamin D activating enzymes, 
with the ability to locally convert inactive vitamin D to its active form 
(Sigmundsdottir et al, 2007). VDRs have been detected in practically all cells 
of the immune system such as B- and T-lymphocytes (Alhassan Mohammed 
et al, 2016), justifying the important role of vitamin D in the immune system 
and immune system related diseases. 
 
 
?-cells 
 
VDRs and 1-?-hydroxylase (an enzyme that converts 25OHD to active 
vitamin D) have been identified in the ?-cells of the pancreas (Bland et al, 
2004). This suggests a role for vitamin D in controlling the function of the 
?-cells, evidenced by the presence of VDREs in the promoter region of the 
human insulin gene (Maestro et al, 2003).  
In the 1980s in animal models, it was already shown that vitamin D 
deficiency inhibits the secretion of insulin and that the secretion can be 
improved by vitamin D administration (Cade and Norman, 1986; Norman et 
al, 1980). In a recent study it was found that maternal vitamin D-restricted 
diet of mice leads to increased blood sugar levels, smaller ?-cell mass and 
lower insulin concentration in the offspring (Maia-Ceciliano et al, 2016), 
highlighting the importance of adequate vitamin D supply during the 
developmental processes. Administration of vitamin D decreases the 
inflammation in the pancreas in a mouse model of type 1 diabetes (Wang et 
al, 2016).  
Human studies have gained mixed results on the capacity of vitamin D to 
improve the release or sensitivity of insulin (Lips et al, 2016). Future studies 
will need to distinguish the effect of vitamin D on the ?-cells in adults or 
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children with an existing disease and the effect of vitamin D during the 
developmental process in-utero for later ?-cell function.  
 
 
HLA gene region 
 
Type 1 diabetes has a strong connection with the HLA gene region (Noble, 
2015). It has been shown that VDREs exist in the promoter region of at least 
certain HLA alleles suggesting that vitamin D has a role in the regulation of 
HLA gene expression (Cocco et al, 2012; Israni et al, 2009; Livingstone 
2009; Ramagopalan et al, 2009). 
 
 
Gut microbiota 
 
Gut microbiota has been suggested as an environmental trigger for type 1 
diabetes (Bibbò et al, 2016). Interestingly, recent novel findings point 
towards a role for vitamin D in modulating the gut microbiota (Kanhere et al, 
2016) and it has been shown that the maternal microbiota in the gut and 
other body sites changes during pregnancy (Nuriel-Ohayon et al, 2016). 
Therefore, discovery of a role of vitamin D in modulating gut microbiota may 
reveal a novel mechanism not presented in the literature to explain the 
various epidemiological associations between vitamin D and type 1 diabetes. 
 
 
Response to vitamin D supplementation 
 
People with an immune-mediated disease such as multiple sclerosis, have a 
weaker response to vitamin D supplementation (Bhargava et al, 2016). This 
observation does not provide a mechanism for associations between vitamin 
D and type 1 diabetes, but highlights the fact that a higher amount may be 
needed to control the disease-associated inflammation. This may translate to 
a higher tolerance of vitamin D supplementation of individuals with immune 
mediated diseases, which should be further investigated.  
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3 AIMS 
Our main aim was to compare the serum 25OHD concentrations during 
pregnancy between mothers whose children later developed type 1 diabetes 
and mothers whose children did not.  
 
Additional aims 
1. Evaluate the prevalence of vitamin D deficiency in pregnant Finnish 
women 
2. Analyse the association between SNPs located in genes in the 
metabolic pathway of vitamin D  and serum 25OHD concentration 
3. Analyse the association between SNPs in the metabolic pathway of 
vitamin D and type 1 diabetes  
4. Analyse the association between HLA genetic polymorphisms and 
serum 25OHD concentration 
 
subjects and methods 
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4 SUBJECTS AND METHODS 
In order to study the possible relationship between maternal vitamin D 
deficiency and the risk for type 1 diabetes in the child, we wanted to measure 
serum 25OHD concentration during pregnancy. In Finland, serum samples 
are collected in the maternity clinics from almost all pregnancies (98%) 
during the end of the first trimester to screen for infectious diseases (The 
Finnish Maternity Cohort; FMC). Samples have been collected since 1983 
and are stored in the Prenatal Serology laboratory in the National Institute 
for Health and Welfare (THL). These samples were ideal for our study 
purposes since we could measure maternal serum 25OHD concentration 
after later development of type 1 diabetes in the children was already known 
– provided that serum 25OHD would be stable enough to be measured years 
after the sample collection. 
 
 
 
4.1 FAMILIES WITH TYPE 1 DIABETIC CHILDREN (CASE 
FAMILIES) 
 
Since the principal investigator of the “Vitamin D and Type 1 Diabetes” study, 
Professor Jaakko Tuomilehto, had done intensive type 1 diabetes research for 
decades, we had a database of families with type 1 diabetic children in THL. 
From this database we were able to identify suitable families for our study. 
We decided to also include a non-diabetic sibling of the patient to be able to 
compare serum 25OHD concentrations in two pregnancies of the same 
mother with a different outcome (a child with or without type 1 diabetes). 
At the time of planning the “Vitamin D and Type 1 Diabetes” study it was 
known that 25OHD is chemically stable. The exact information on the 
duration of storage after which serum 25OHD concentration could still be 
measured reliably, however, was lacking. Earlier we had found that there was 
no difference in the mean serum 25OHD concentration between samples 
stored for 15-20 years (mean concentration 37.2 nmol/l; n = 45) and for 9-14 
years (mean concentration 37.2 nmol/l; n = 31). Based on this result and 
based on the decades of experience in vitamin D analytics of the co-principal 
investigator of our project, Professor Christel Lamberg-Allardt (University of 
Helsinki), we decided to choose 20 years as the maximum storage time. Thus 
we chose 1994 as the earliest possible birth year for the patients with type 1 
diabetes. Later it was discovered that no significant degradation of 25OHD in 
serum occurs during at least the first 24 years of storage in -20°C 
(Agborsangaya et al 2010). 
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The THL database contained 751 families with type 1 diabetic children 
born 1994 or later in the database (case families). We confirmed with power 
calculations that this number was large enough to achieve our main aim: to 
compare serum 25OHD concentrations in case and control mothers. A case-
control study setting was thought to serve our study purposes best and 
therefore we decided to include control families. 
 
 
4.2 FAMILIES WITH NON-DIABETIC CHILDREN 
(CONTROL FAMILIES) 
 
Since our main aim was to compare serum 25OHD concentrations during 
pregnancies of mothers whose children later developed type 1 diabetes (case 
mothers) to that of mothers whose children did not, we needed control 
mothers with non-diabetic offspring. Seasonal variation in serum 25OHD 
concentrations is considerable in Finland (Virtanen et al, 2011), so we 
decided to match the case and control mothers according to the serum 
sample collection time. Serum samples of the control mothers were selected 
so that the samples of the case and control mother pairs were collected 
during the same day. To ensure a sufficient sample size, we chose 2 control 
mothers for each case mother. 
 
 
 
4.3 INVITING OF THE STUDY SUBJECTS 
 
In case families, an invitation letter was sent to the parents, to the diabetic 
child and to a non-diabetic sibling of the patient, if available. If there were 
several siblings, we invited the oldest one (born 1994 or later). In control 
families an invitation letter was sent to the parents and the control child. 
Altogether around 5200 persons were invited to participate. The contact 
information of the case families was available in the THL database. The 
contact information of the control families was obtained from the National 
Population Registry.  
 
 
 
4.4 SAMPLES 
 
We asked for written informed consent from all invited mothers to use the 
FMC serum sample for 25OHD concentration measurement. The FMC serum 
samples are collected during the end of first trimester of pregnancy and 
stored in -20?C. The duration of pregnancy is on average 40 weeks. The first 
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trimester of pregnancy consists of weeks 1-12, the second trimester of weeks 
13-28 and the third trimester of weeks 29-40. The exact week of pregnancy of 
each serum sample was not known in this study. 
We asked for a saliva sample for DNA extraction from all participants. We 
chose to collect saliva samples for DNA extraction instead of blood samples 
for four  reasons; 1) there was a relatively new promising kit available 
(Oragene® kits, DNA Genotek Inc. Ottawa, Canada) that did not seem to 
have the same problems with DNA yield and quality than the previous saliva 
extraction methods; 2) samples could be stored at room temperature for a 
relatively long time in contrast to blood samples that need to be stored 
in -20?C; 3) sample collection kits could be sent to the homes of the 
participants instead of them needing to go to a health centre, which we hoped 
would increase the participation rate; 4) we had children in our study group 
and therefore a non-invasive home-based sample collection method was 
considered more convenient for the children compared to collecting blood 
samples. 
 
 
 
4.5 LABORATORY ANALYSES AND THE RELIABILITY OF 
THE RESULTS  
 
Serum 25OHD concentration measurement  
Serum 25OHD concentrations were measured in the laboratory of Professor 
Christel Lamberg-Allardt to indicate the vitamin D status of the mothers 
during their pregnancies. Measurement of this metabolite provides the best 
estimate of an individuals’ vitamin D status because it is not significantly 
regulated and it has a rather long serum half-life (approximately 3 weeks) 
thus providing an indication of vitamin D stores obtained from both UV 
radiation and dietary/supplement intake over long periods (Zerwekh, 2004).  
The serum 25OHD concentrations were analysed with enzyme-linked 
immunosorbent assay method with IDS OCTEIA 25-Hydroxy Vitamin D kits, 
(Immunodiagnostic Systems Ltd., Boldon, UK). The method is based on the 
binding of specific antibodies to 25OHD in the samples.  
It is important to note that serum 25OHD is relatively difficult to 
quantitate and therefore the analyses require a strong quality control. In our 
study, the analyses were done in a laboratory with decades of experience in 
vitamin D analytics and the quality and accuracy of the serum 25OHD 
analysis was assured on an ongoing basis by participation in the international 
vitamin D External Quality Assessment Scheme (DEQAS, Charing Cross 
Hospital, London UK). DEQAS was established in 1989 to ensure analytical 
reliability of 25OHD assays (Carter et al 2004). The intra- and inter-assay 
coefficients of variation were 3.57 % and 3.68 %. 
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Vitamin D status was classified as follows: 
<25 nmol/l  severe vitamin D deficiency 
25-49 nmol/l vitamin D deficiency/insufficiency 
50-75 nmol/l sufficient vitamin D status 
>75 nmol/l  optimal vitamin D status  
 
 
This classification is based on the view that seemed to be universal among 
vitamin D researchers at the time. Later in 2011, the Institute of Medicine in 
the United States suggested that the threshold for vitamin D deficiency of at 
least 50 nmol/l is high enough to cover the requirements of 97.5% of the 
population in Northern America (IOM, 2011). This report has further 
strengthened the view of setting 50 nmol/l as the threshold for vitamin D 
deficiency.  
 
Vitamin D metabolism related genotyping 
 
For DNA extraction, 2 ml of saliva was collected from all participants using 
Oragene® kits (DNA Genotek Inc. Ottawa, Canada) (Rogers et al, 2007). In 
the instructions that were sent to each participant with the Oragene kit, the 
participants were asked to rinse their mouth with water to remove food 
particles and then give 2 ml of saliva to the Oragene sample collection vial 
and close the cap. Oragene antibacterial solution stabilizes the DNA and 
enables the sample to be stored and shipped at room temperature. The DNA 
extraction was done with the reagents included in the Oragene kits with a 
modification to the kit instructions: we added an extra purification step with 
70% ethanol since the DNA extracted with the kit instructions did not work 
properly in the PCR. The DNA samples were stored in -20°C until analysis.  
Genotyping of the SNPs in genes in the metabolic pathway of vitamin D 
was done with TaqMan assay (Applied Biosystems, Paisley, United Kingdom) 
in the laboratory of the co-principal investigator of the “Vitamin D and Type 
1 Diabetes” study, Professor Graham A. Hitman (Barts and the London 
School of Medicine and Dentistry). The Hardy-Weinberg equilibrium was 
tested and 10% of the genotyping was done in duplicate. For part of the 
samples, the correctness of the results of the children was confirmed based 
on the genotyping results of the parents. A total of 31 SNPs in genes in the 
metabolic pathway of vitamin D were initially selected on basis of previously 
published associations with serum 25OHD concentration.  
 
HLA genotyping  
 
HLA genotyping was performed using sequence-specific primers (Dynal 
AllSet+ SSP, Dynal Biotech Ltd, Bromborough, UK). Dynal? Allset™). 
HLA-B, -DRB1 and -DQB1 genes were selected for HLA genotyping based on 
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their previously published associations with type 1 diabetes (Pociot et al, 
2010).   
The HLA-B is highly polymorphic, and thus the number of participants 
carrying a certain HLA-B allele was in most cases small. Therefore, HLA-B 
alleles present in our study population were grouped into supertypes 
according to Sidney et al (2008) as follows: Supertype B07 (B*07, B*35, 
B*51, B*55, B*56), B08 (B*8), B27 (B*14, B*27, B*38, B*39, B*48), B44 
(B*18, B*37, B*40, B*44), B58 (B*57, B*58)and B62 (B*15). The HLA-B 
alleles B*13 and B*47 do not belong to any of the HLA-B supertypes. Some of 
the HLA-B supertypes and unclassified B alleles (B58 supertype, n=8; B*13 
allele, n=11; B*47 allele, n=2), and some of the HLA-DRB1 alleles (DRB1*10, 
n=10; DRB1*12, n=24; DRB1*14, n=21; DRB1*16, n=7) were not analysed 
separately due to small sample size. When possible, the correctness of the 
results of the children was confirmed based on the genotyping results of the 
parents. 
 
 
 
4.6 STATISTICAL ANALYSES 
 
When planning the study, we had to define the difference in serum 25OHD 
concentrations that we would want to detect between the case and control 
mothers. No information existed on how large of an increase or decrease in 
serum 25OHD concentration would cause physiological effects. Therefore, we 
decided to plan the study so that it would detect a relatively small difference 
(5 nmol/l) between the case and control mothers. At a two-sided 1% 
significance level (?), and statistical power of 90% (?), the needed sample 
size was 540; 270 cases and 270 controls (assuming standard deviation of 
15 nmol/l in serum 25OHD concentrations). 
Since there were 751 families with type 1 diabetic offspring in the THL 
database, we needed at least 270/751 (36%) of the invited mothers to 
participate. Since we needed 270 case-control mother pairs, and not just any 
270 participants from the case and control mother groups, we estimated that 
we would need around 50% of the invited mothers to participate. We did not 
calculate sample size for the genetic analyses since it was not possible to 
increase the sample size (only 751 families fulfilling the criteria were 
available). Considering the genetic analyses, we decided to invite all families 
fulfilling our inclusion criteria (although the mere serum 25OHD 
concentration comparison could have been done with a smaller sample size). 
Statistical analyses were performed using PASW statistics 18 for Windows 
(Released 2009, Chicago: SPSS Inc.), Intercooled Stata10 for Windows 
(StataCorp. 2007. Stata Statistical Software: Release 10. College Station, 
TX: StataCorp LP) and SAS 9.3 (SAS Institute Inc., Cary, NC). Since serum 
25OHD concentrations are known to have considerable seasonal variation in 
Finland, all analyses were adjusted for month of sample collection. This was 
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not, however, needed when we compared maternal serum 25OHD 
concentrations between case and control mothers since the samples of each 
case-control pair were matched according to the date of sample collection.   
The mean serum 25OHD concentrations were compared with a Student´s 
t-test and with Pearson’s ?2 test. Linear regression modelling was used when 
adjustment for the month of sample collection was needed. When we tested 
mother type difference, interaction term between case and control mothers 
was incorporated into the models.  
P values <0.05 were considered statistically significant. Multiple testing 
was controlled for using the false discovery rate (FDR) method (step-up 
procedure described by Benjamini and Hochberg (Benjamini and Hochberg, 
1995). If the original p value was smaller than the Benjamini-Hochberg 
critical value, the difference in genotype distribution was considered 
statistically significant.  
 
 
 
4.7 IDENTIFYING CRITICAL STEPS AND SOURCES OF 
ERROR   
 
Before initiating the “Vitamin D and Type 1 Diabetes” study, we tried to 
identify the critical steps and sources of error. The risks related to the 
reliability or quality control of the laboratory analyses and their solutions 
were described in a previous chapter (please see 4.5 for more information). 
In addition, we identified the following risks: 
 
1. The saliva sample may not be from the person it was supposed to be  
 
Solution: The saliva samples were collected by the participants themselves in 
their homes. To decrease the probability that the saliva sample collection 
tubes would switch by mistake between the invited family members, we 
decided to pack the study information including the tubes individually to 
each family member. We also wrote the first name of each family member 
with large letters to the sample collection tubes. Though, a possibility that a 
part of the sample collection tubes have been switched still exists. We 
estimated that the proportion of switched samples would be low and would 
therefore have only a minor impact on the results.  
 
2. The number of the participants would not be sufficient  
 
Solution: According to the power calculations, we would need around 50% of 
the invited mothers to participate. We thought this was achievable and 
considered the risk for not being able to recruit enough participants low. We 
did not know, however, if the sample size would be large enough to perform 
the genetic analyses (SNP and HLA). Therefore, we planned alternative 
subjects and methods 
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manners to perform the analyses. We decided to group HLA alleles into 
larger groups (supertypes) if the sample size would be too small to analyse 
HLA alleles separately. 
 
3. Some of the children classified as non-diabetic control children or 
non-diabetic siblings may in fact be type 1 diabetes patients. They may 
not be included in our database of families with type 1 diabetic 
children, or the non-diabetic children may have developed type 1 
diabetes after the last update of our database. 
 
Solution: We included a short questionnaire in the study, where the disease 
status was asked from all participants. We excluded those control children 
and non-diabetic siblings that had type 1 diabetes. An uncertainty, however, 
remained as to whether some of the control children and non-diabetic 
siblings would develop type 1 diabetes during the study, but we estimated 
that this would only have a minor impact on the results. 
 
4. The requested serum sample may not be available in the FMC.  
 
Solution: We were told by the Prenatal Serology laboratory (THL) that is in 
charge of the FMC samples, that usually over 90% of samples are available 
for any research project done with the FMC samples. Since we selected two 
control families for each case family, we considered that this risk would 
concern mainly the samples of the case mothers. 
 
 
5. The FMC serum samples may have been thawed several times after 
the collection and initial storage. 
 
Solution: We contacted the Prenatal Serology laboratory (THL) and asked 
whether it was likely that the samples had been thawed several times, which 
could possibly cause either evaporation of the samples or degradation of 
25OHD, or both. We were told that it is unlikely that a significant proportion 
of the samples would have been used or that the samples would have been 
thawed multiple times. Although we did not have the exact information on 
whether the samples had been thawed or not, we estimated this risk low and 
decided to accept it. 
 
6. The DNA quality and quantity in the saliva samples 
 
Solution: The fact that there would be no health care personnel collecting the 
samples but they would be collected at homes of the participants, could affect 
whether the instructions were followed correctly and therefore the quality 
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and quantity of the samples. We included figures of different steps of the 
sample collection in the instructions to decrease the risk for incorrect sample 
collection.  
Although the quality reports form the manufacturer (DNA Genotek Inc.) of 
the saliva kit seemed impressive, we did not know whether the DNA quality 
would be good enough for our purposes. Therefore, we performed a pilot 
testing of the Oragene kits. We considered both the DNA yield and quality 
satisfactory. 
 
 
4.8 ETHICAL CONSIDERATIONS  
 
Informed written consent was collected from all participants. The consents of 
the children were signed by their legal guardians. There was no benefit for 
the participants to take part in the study and no compensation was paid. The 
study subjects and families were assigned a study-ID numbers according to 
the prevailing practice in THL. The genetic information was not given to the 
participants. The study plan was approved by the Coordinating Ethics 
Committee of the Hospital District of Helsinki and Uusimaa (168/E0/2006). 
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5 RESULTS AND THEIR EVALUATION 
 
5.1 STUDY PARTICIPANTS AND SAMPLES (I-IV) 
 
The samples collected in the “Vitamin D and Type 1 Diabetes” -study were 
used in all the individual studies of this thesis (I-IV). Initially, 751 families 
with type 1 diabetic children (case families) were selected from the THL 
database. We pre-selected two control families (families with a non-diabetic 
child) for each case family. If the first control family did not participate, we 
invited the other. The final number of DNA samples received and serum 
25OHD concentration results obtained are presented in figure 3. The total 
number of serum 25OHD concentration results was 1044 and DNA samples 
2854. The number of successful SNP/HLA analysis results varied according 
to the SNP/HLA allele. 
The main reason for a missing sample was that the invited persons did 
not react to our invitation or reminder letter. Over 90% of the mothers that 
participated in our study had a serum sample available in the FMC. Over 
99% of the serum 25OHD concentration analyses were successful. Over 95% 
of the DNA extractions and over 90% of the SNP and HLA analyses were 
successful. The main reason for unsuccessful DNA extractions or genetic 
analyses was a poor quality of the saliva sample or DNA sample derived from 
the saliva sample.  
Serum 25OHD concentration was measured and SNP analyses were done 
in all samples. Due to high costs, HLA genotyping was only performed in part 
of the DNA samples (~40% of all samples).  
In the end, 343 case-control pairs (46% of the selected case-control pairs) 
with a successful serum 25OHD concentration measurement were included. 
According to our power calculations 270 case-control pairs were needed. The 
sample collection was therefore evaluated successful.  
A higher percentage of the invited case families participated than of the 
control families, even though we pre-selected two control families for each 
case family. This is likely to result from higher motivation among families 
with a diabetic child. Since we had a case-control study setting, possible 
differences between the participants and non-participants can be assumed to 
be similar among the case and control families and therefore not likely to 
cause biases.  
 
 
results and their evaluation 
50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
751 + 751 control families selected 
348 mothers with a 
DNA sample and a 
25OHD result  
418 mothers  
with a 25OHD result 
381 DNA 
samples from 
children 
343 case and  
control mother pairs 
with 25OHD results  
379 DNA 
samples from 
mothers 
340 DNA 
samples 
from fathers  
751 case families selected 
137 mothers 
with a 25OHD 
result from 
non-diabetic 
sibling 
pregnancy 
 
238 DNA 
samples 
from 
non-diabe
tic siblings 
379 mothers 
with a DNA 
sample and a 
25OHD result 
343 case and 
control mother 
pairs with 25OHD 
results 
512 DNA 
samples 
from 
mothers 
 
470 DNA 
samples 
from 
fathers 
 
534 DNA 
samples 
from 
diabetic 
children 
1754 DNA samples 489 
mothers 
with a 
25OHD 
result from 
case 
pregnancy 
 
1100 DNA samples 
 
 
 
Figure 3. Participants of the “Vitamin D and Type 1 Diabetes” study. Final number of DNA 
samples and serum 25-hydroxyvitamin D (25OHD) concentration results separately for case and 
control families. 
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Final number of participants/samples in the individual studies: 
 
I) 343 case and control mother pairs with serum 25OHD concentration 
results, 137 case mothers with a serum 25OHD result from a pregnancy of a 
non-diabetic sibling of the diabetic child.  
 
II) 474 case and 348 control mothers with both a serum 25OHD 
concentration result and a DNA sample available. DNA samples from 512 
case mothers, 470 case fathers, 534 type 1 diabetic children, 238 non-diabetic 
siblings, 379 control mothers, 340 control fathers, 381 control children.  
 
III) 474 case and 348 control mothers with both a serum 25OHD 
concentration result and a DNA sample available.  
 
IV) 395 mothers (216 case and 179 control mothers) with a HLA-B result, 501 
mothers (264 case and 237 control mothers) with a HLA-DRB1 result and 
475 mothers (236 case and 239 control mothers) with a HLA-DQB1 result 
available. 
 
 
 
5.2 VITAMIN D DEFICIENCY IN PREGNANT FINNISH 
WOMEN (I-IV)  
 
 
In the “Vitamin D and Type 1 Diabetes” study, a serum 25OHD concentration 
result was available from 1044 pregnancies. Serum samples were collected 
during the first trimester of pregnancy with diabetic children, non-diabetic 
siblings and control children.  
Only 5.4% of the pregnant women had a serum 25OHD concentration that 
is considered optimal and more than two thirds (68.9%) of the mothers 
presented with vitamin D deficiency or insufficiency (Figure 4).  
The mean serum 25OHD concentration in all samples was 44.4 nmol/l. 
The lowest serum 25OHD concentration detected was 14.3 nmol/l and the 
highest 173.1 nmol/l.  
Studies on vitamin D status during pregnancy in Finland are scarce, but 
similar results to ours have been found. When evaluating results obtained in 
different studies, it needs to be remembered that serum 25OHD is relatively 
difficult to quantitate and therefore the absolute serum 25OHD 
concentrations obtained with different methods cannot be directly compared 
(Lips et al, 1999). For example, one study analysed the proportion of vitamin 
D deficiency in the same set of samples using three different methods. The 
results were 8%, 22% and 43% depending on the method (Snellman et al, 
2010).  
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Figure 4. The percentage of samples of the “Vitamin D and type 1 diabetes” study in each 
category describing vitamin D status (n=1044) 
 
 
 
 
Three Finnish studies using samples that were collected during 
approximately the same time period as our samples found serum 25OHD 
concentrations of 26-44 nmol/l in pregnant women (Kuoppala et al 1986; 
Munger et al 2016; Toriola et al 2009). Since then, there have been some 
changes that may have improved the vitamin D status in Finland. The 
fortification of milk and margarine with vitamin D started in 2003 (Ministry 
of Trade and Industry of Finland, 2002) and the general vitamin D related 
awareness has increased considerably leading to a higher consumption of 
vitamin D supplements (Raulio et al, 2016). A study that used FMC samples 
collected in 2007, however, did not show an improved vitamin D status 
during pregnancy (Viljakainen et al 2010). In other population groups an 
improvement in the vitamin D status has been shown. The mean serum 
25OHD concentrations in Finland have increased both in children and adults 
(Ministry of Social Affairs and Health, 2006; Raulio et al, 2016). 
Unfortunately, recent studies on vitamin D status in pregnant Finnish 
women are lacking. 
A recent systematic review provided a global summary of the vitamin D 
status of pregnant women (Saraf et al, 2016). It was found that in general, the 
highest maternal serum 25OHD concentrations are found in Africa (mean 
92 nmol/l), the Americas (60 nmol/l) and the Western Pacific (57 nmol/l), 
and the lowest in the Eastern Mediterranean (20 nmol/l), Europe (30 
nmol/l) and South-East Asia (30 nmol/l), although the differences in the 
methods used affect the results.    
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5.3 SEASONAL VARIATION IN SERUM 25OHD 
CONCENTRATIONS (I-IV)  
 
 
Using all serum samples we received in the “Vitamin D and Type 1 Diabetes” 
study (n=1044), we calculated the mean serum 25OHD concentrations in 
samples collected during the different months of the year (Figure 5). A clear 
and expected seasonal variation was seen (figure 5). Figure 5 shows that the 
effect of higher UV radiation exposure during the summer months extends to 
the autumn months. This highlights the need for vitamin D supplementation 
especially during the winter and spring months. 
 
 
 
 
 
 
 
Figure 5. Serum 25-hydroxyvitamin D (25OHD) concentrations collected during different months 
in all samples of the “Vitamin D and type 1 diabetes” study (n=1044) 
 
 
 
The seasonal variation in serum 25OHD concentrations in Finland is a 
well-known fact, documented in several studies (Agborsangaya et al 2010; 
Holmlund-Suila et al, 2013; Virtanen et al, 2011). The same kind of seasonal 
pattern also exists, for example, in Sweden (Klingberg et al, 2015) and 
Norway (Jorde et al, 2010), but even in the southern parts of Europe, like 
Portugal, a clear difference between the serum 25OHD concentrations during 
the winter and summer months can be seen (Bettencourt et al, 2016).  
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5.4 SERUM 25OHD CONCENTRATIONS SIMILAR DURING 
PREGNANCY IN CASE AND CONTROL MOTHERS (I)  
 
Serum 25OHD concentration was available from 343 case-control mother 
pairs. We compared the serum 25OHD concentrations of case and control 
mothers in samples collected during the first trimester of pregnancy. There 
was no difference in the mean serum 25OHD concentrations between the 
case and control mothers. The mean serum 25OHD concentration during the 
pregnancy of the case mothers was 43.9 nmol/l (n=343; SD=16.9) and 43.5 
nmol/l (n=343; SD=16.6) for the control mothers (p=0.70).  
We also compared the proportions of samples from case and control 
mothers belonging to each category that describes vitamin D status. The 
comparison between proportion of case and control mothers with severe 
vitamin D deficiency (<25 nmol/l), insufficiency (25-49 nmol/l), with a 
sufficient vitamin D status (50-75 nmol/l) and with an optimal vitamin D 
status (>75 nmol/l) is illustrated in figure 6. No difference was found 
between case and control mothers in the proportions in each category 
(p=0.88). 
Two studies investigating the association of maternal/neonatal vitamin D 
status with type 1 diabetes risk in the child have published their results after 
we started our study.  
In a Norwegian study, with a very similar study setting to ours, an 
association was found between maternal serum 25OHD concentration and 
type 1 diabetes risk in the child (Sørensen et al, 2011). The difference is that 
the serum samples were mainly collected during the last trimester of 
pregnancy. The mean serum 25OHD concentrations were also considerably 
higher (65.8 nmol/l in case and 73.1 nmol/l in control mothers). The results, 
however, cannot be directly compared since the measurements were done 
with different methods.  
In a recent Danish study, serum 25OHD concentrations were measured in 
neonatal dried blood spots from children that later developed type 1 diabetes 
and from non-diabetic control children (Jacobsen et al, 2016). No association 
between neonatal vitamin D status and type 1 diabetes risk was found. The 
median serum 25OHD concentrations were low (<30 nmol/l), but cannot be 
directly compared since the samples were from children and the sample 
collection method (dried blood spots) was different from ours and the 
Norwegian study. 
 
 55 
 
 
 
Figure 6. The proportion of serum 25-hydroxyvitamin D (25OHD) concentration results in each 
category defining the vitamin D status in case and control mothers (343 case-control pairs). 
 
 
 
In older studies assessing the relationship between vitamin D and type 1 
diabetes, the use of vitamin D supplements or cod-liver oil during pregnancy 
and during the first years of life have in some studies been associated with a 
lower the risk for type 1 diabetes in the child (The EURODIAB Substudy 2 
Study Group, 1999; Hyppönen et al, 2001; Stene et al, 2000). This 
association has, however, not been seen in all studies. Comparing our results 
to these studies, where information on the vitamin D intake is based only on 
the supplement use, is difficult, since vitamin D status is influenced by 
several other factors as well such as exposure to UV radiation, BMI, physical 
activity and smoking (Miettinen et al 2014, Skaaby et al, 2016). We had the 
possibility of measuring the actual serum 25OHD concentration, which 
results from all these factors.  
Considering the discrepancy in the results of all studies in the field, it is 
justified to assume that the possible association between vitamin D and type 
1 diabetes is not likely to be as straightforward as has been initially 
suggested.      
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5.5 SNPs IN THE METABOLIC PATHWAY OF VITAMIN D 
ASSOCIATE WITH SERUM 25OHD CONCENTRATION IN 
FINNISH WOMEN (II) 
 
 
We selected 31 SNPs in 8 genes based on previously found associations with 
serum 25OHD concentration, type 1 diabetes, or both. All the SNPs were in 
Hardy–Weinberg equilibrium except SNP rs7975232 localised to the VDR 
gene, which was removed from further analyses. Of the genotypes, 100% 
were concordant in 120 duplicate samples. 
First we wanted to test which of the selected SNPs associated with serum 
25OHD concentration in our study, since it had not been previously studied 
in the Finnish population. In order to test this, we selected all persons that 
had both serum 25OHD concentration and SNP genotyping results available 
(822 persons). Since the serum 25OHD concentrations were only available 
from the mothers, the 822 persons were all either case or control mothers. 
We found a nominal association (p?0.05) between serum 25OHD 
concentration and 13 SNPs in four genes (NADSYN1/DHCR7, VDR, GC and 
CYP27A1; table 1). 
 
 
 
Table 1. Association between SNPs in the metabolic pathway of vitamin D and serum 
25-hydroxyvitamin D (25OHD) concentration.  
 
 
SNP Gene p 
rs4945008 NADSYN1/DHCR7 0.03 
rs12785878 NADSYN1/DHCR7 0.02 
rs4944957 NADSYN1/DHCR7 0.05 
rs7944926 NADSYN1/DHCR7 0.02 
rs3794060 CYP27A11/DHCR7 0.02 
rs12800438 NADSYN1/DHCR7 0.02 
rs4516035 VDR 0.02 
rs731236 VDR 0.03 
rs1544410 VDR 0.03 
rs10783219 VDR 0.02 
rs12512631 GC 0.03 
rs4588 GC 0.05 
rs17470271 CYP27A1 0.03 
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Since our analyses, several studies have evaluated the genetic determinants 
of serum 25OHD concentration in the Finnish population. These studies 
have confirmed, for example, the associations of rs12785878 
(NADSYN1/DHCR7) and rs4588 (GC) with serum 25OHD concentration 
(Pekkinen et al; 2014; Voipio et al 2015). In other populations, the role of 
genes as determinants of serum 25OHD concentration has been shown in 
several studies (Abbas et al, 2008; Ahn et al, 2010; Engelman et al,2008; 
Fang et al, 2009; Jolliffe et al, 2016; McGrath et al, 2010; Wang et al, 2010).  
 
 
 
5.6 GENOTYPES OF SNPs IN THE VITAMIN D RECEPTOR 
(VDR) GENE DISTRIBUTE DIFFERENTLY IN THE CASE 
AND CONTROL MOTHERS (II) 
 
 
Altogether we received 2854 DNA samples from the case and control families 
to study the role of SNPs in the metabolic pathway of vitamin D as 
determinants of type 1 diabetes risk in the child (DNA samples of 512 case 
mothers, 470 case fathers, 534 type 1 diabetic children, 238 non-diabetic 
siblings, 379 control mothers, 340 control fathers, 381 control children).  
After confirming an association between certain SNPs in the metabolic 
pathway of vitamin D with serum 25OHD concentration, we wanted to test a 
possible difference in the genotype distribution of these SNPs between the 
case and control families. Our main interest was comparing the type 1 
diabetic and control children, but we included all family members in the 
analyses. We compared the case and control mothers, the case and control 
fathers as well as the type 1 diabetic children and their non-diabetic siblings. 
We did not find any difference in the genotype or allele distribution 
between the type 1 diabetic  children and  control children. We did, however, 
find a difference in the genotype distribution of three SNPs between the case 
and control mothers (table 2). All three SNPs were localised to the VDR gene 
(rs1544410, p=0.007; rs731236, p=0.003; and rs4516035, p=0.015) (table 2). 
Two SNPs (rs1544410 and rs731236) remained statistically significant after 
correction for multiple testing with FDR.  
No differences in the genotype or allele distributions emerged between 
the case and control fathers, or between the type 1 diabetic children and their 
non-diabetic siblings. In the case families, no allele of the 13 SNPs studied 
was preferentially transmitted to the type 1 diabetic children. 
Our finding suggests that maternal genetic factors modify type 1 diabetes 
risk in the child, independent on the child´s genotype, although the overall 
effect may not be strong given the multifactorial nature of the disease. To our 
knowledge the finding is novel and no previous studies exist. Thus far the 
focus in type 1 diabetes related genetic studies has been on the affected child 
results and their evaluation 
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and the idea of an independent role of maternal genetic factors has not been 
presented.  
 
 
 
Table 2. Genotype distributions of SNPs in the vitamin D receptor (VDR) in case and control 
mothers.  
amultiple testing correction with false discovery rate (FDR) approach (Benjamini-Hochberg 
step-up procedure). If the original p value was less than the Benjamini-Hochberg critical value, it 
was considered statistically significant  
*statistically significant after multiple testing correction with FDR approach.   
 
 
SNP Case 
mothers 
Control 
mothers 
OR (95% CI) p Benjamini-
Hochberg 
critical 
valuea 
rs1544410 (VDR)    0.007* 0.008 
Genotypes n (%)      
AA 48 (10.2) 42 (12.0) 0.85 (0.58-1.26) 0.41  
AG 227 (48.1) 130 (37.0) 1.30 (1.10-1.53) 0.0016  
GG 197 (41.7) 179 (51.0) 0.81 (0.70-0.94) 0.0062  
rs731236 (VDR)    0.003* 0.004 
Genotypes n (%)      
CC 49 (9.9) 43 (12.3) 0.80 (0.55-1.18) 0.26  
CT 243 (49.0) 130 (37.2) 1.32 (1.12-1.55) 0.0007  
TT 204 (41.1) 176 (50.4) 0.82 (0.70-0.95) 0.0075  
rs4516035 (VDR)    0.015 0.012 
Genotypes n (%)      
CC 124 (25.1) 63 (18.4) 1.37 (1.04-1.79) 0.0215  
CT 225 (45.5) 189 (55.1) 0.83 (0.72-0.95) 0.0066  
TT 145 (29.4) 91 (26.5) 1.11 (0.89-1.38) 0.37  
 
 
 
 
The phenomenon that maternal genetic factors affect the disease risk or the 
development of the child independent on the child´s genotypes, however, has 
been presented outside the field of type 1 diabetes research. The maternal 
genetic factors have previously been shown to associate with the child’s brain 
morphology and cognitive development (Pilsner et al, 2010; van der Knaap, 
2014) and risk for several diseases, for example autism and atopic dermatitis 
(Esparza-Gordillo et al, 2015; James et al 2010). One previous study covers 
results related with the VDR gene. The allele frequency of SNP rs2228570 in 
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the VDR gene was shown to differ between mothers with a preterm birth and 
those with a full-term birth (Manzon et al, 2014).  
The mechanism explaining the relationship between certain maternal 
VDR genotypes and type 1 diabetes risk in the child is not clear and can only 
be speculated at this point. Type 1 diabetes is a disease that can develop early 
in life. Type 1 diabetes-associated autoantibodies that precede the diagnosis 
of type 1 diabetes can appear within months of birth, which suggests a foetal 
programming of the disease (Siljander et al, 2009). It is possible that the 
variation in the maternal VDR gene modifies the various effects of vitamin D 
(through the action of its receptor). This may be especially apparent when 
the amount of circulating 25OHD is not adequate. In a meta-analysis it was 
suggested that the association between the polymorphism of the VDR gene 
(of the patient) and type 1 diabetes is influenced by the vitamin D status 
(Tizaoui et al, 2014).  
The effects of the VDR gene are also dependent on other genes. The 
Diabetes Autoimmunity Study in the Young (DAISY) study showed that 
interaction between the VDR and protein tyrosine phosphatase, non-receptor 
type 2 gene (PTPN2), affects the risk for type 1 diabetes (Frederiksen et al, 
2013b). In this study an association of certain maternal SNPs of the VDR 
gene with the risk for type 1 diabetes in the child was seen. It is possible that 
other SNPs in the metabolic pathway of vitamin D not included in our study, 
however, affect the risk for the disease as well, either independently or 
interacting with other SNPs or environmental factors.  
The VDR is a transcription factor with more than 500 target genes. We 
did not see any difference in the genotype distributions of the SNPs in the 
VDR gene between the diabetic patients and the non-diabetic control 
children. This may result from the fact that we only selected a few SNPs of 
the VDR gene.  Our results suggest that the VDR gene associates with the in-
utero environment and the developmental processes in the foetus. Further 
studies are needed but ours and previous studies suggest an important role 
for the VDR in defining the relationship between vitamin D and type 1 
diabetes.  
 
 
 
 
5.7 GENETIC DETERMINANTS OF SERUM 25OHD 
CONCENTRATION ARE DIFFERENT IN THE CASE AND 
CONTROL MOTHERS (III)  
 
 
In our earlier study (II), we showed that certain genotypes in the VDR 
distribute differently in the case and control mothers, suggesting a role for 
the maternal VRD in the development of type 1 diabetes in the child. We 
decided to re-analyse our data on the association between SNPs in the 
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metabolic pathway of vitamin D and serum 25OHD concentrations 
separately for the case and control mothers to detect other vitamin D 
genetics related differences.   
Earlier, we confirmed a statistically significant association between 13 
SNPs in genes in the metabolic pathway of vitamin D and serum 25OHD 
concentration (II). Afterwards, we noticed that six SNPs in 
NADSYN1/DHCR7 and two SNPs in the VDR (rs731236 and rs1544410) were 
in strong linkage disequilibrium and thus had similar associations with 
serum 25OHD concentration. When re-analysing the data separately for the 
case and control mothers, we randomly selected only one SNP of these SNP 
groups resulting in the final number of 7 SNPs in the analyses.   
We detected a difference in the association of SNPs with serum 25OHD 
concentration between the case and control mothers. An interaction test 
indicated that association of two SNPs with serum 25OHD concentration 
differed between case and control mothers (table 3). Rs12512631 in the GC 
gene and rs4516035 in the promoter region of the VDR gene associated 
stronger with serum 25OHD concentration in case (p=0.002 and 0.0002) 
versus control (p=0.64 and 0.83) mothers (p interaction=0.02 and 0.03) 
(figure 7a and 7b).  
 
 
 
Table 3. Association between serum 25-hydroxyvitamin D (25OHD) concentration and SNPs in 
genes in the metabolic pathway of vitamin D in the case and control mothers, and according to 
the presence of the effect allele (EA).  
*The effect allele (EA) is the allele that increases the 25-hydroxyvitamin D concentration 
**Statistically significant interaction 
 
 
SNP (gene) Case 
mothers  
Control 
mothers 
Effect of presence of the effect allele  
 p (n) p (n) EA* p cases p controls p interaction 
rs4945008 
(NADSYN1/DHCR7) 
0.20 (445) 0.054 
(325) 
G 0.093 0.034 0.89 
rs4516035 (VDR) 0.0038 (445) 0.93 (321) T 0.0002 0.83 0.031** 
rs1544410 (VDR) 0.093 (427) 0.32 (326) A 0.043 0.20 0.58 
rs10783219 (VDR) 0.037 (437) 0.55 (317) T 0.0076 0.35 0.23 
rs12512631 (GC) 0.021 (435) 0.67 (324) C 0.0020 0.64 0.023** 
rs4588 (GC) 0.051 (419) 0.65 (322) C 0.019 0.50 0.26 
rs17470271 
(CYP27A1) 
0.052 (428) 0.49 (325) T 0.028 0.86 0.21 
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Figure 7a. In the case mothers the presence of a C allele is associated with an average increase 
of 3.9 nmol/l in serum 25-hydroxyvitamin D (25OHD) concentration (p=0.002) while in the control 
mothers such an association was not found (p=0.64) (p interaction=0.02). 
 
 
 
 
 
 
 
Figure 7b. In the case mothers the presence of a T allele is associated with an average increase 
of 4.06 nmol/l in serum 25-hydroxyvitamin D (25OHD) concentration (p=0.0002) while in the 
control mothers such an association was not found (p=0.83) (p interaction=0.03). 
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The finding is novel and no previous studies exist. It has, however, been 
shown that associations between SNPs and an outcome are influenced by 
environmental factors such as age and gender. For example, several SNPs 
associate more strongly with fat distribution in women than in men (Heid et 
al, 2010). Several SNPs have also shown stronger effects on BMI in younger 
than older people (Winkler et al, 2015). Smoking can also drastically alter the 
effects of SNPs. Certain SNPs have been found to associate with low BMI in 
smokers, but with high BMI in non-smokers (Taylor et al, 2014). Recently it 
was shown that sunlight exposure may modify the association between SNP 
in the VDR and serum 25OHD concentration so that the lowering effect of 
the SNP in the VDR on serum 25OHD concentration is smaller when the 
sunlight exposure is increased (Livingstone et al, 2016). It seems that certain 
SNPs only associate with serum 25OHD in men, and that the associations 
between SNPs in genes in the metabolic pathway of vitamin D and serum 
25OHD concentrations are weaker with increasing age (Miettinen et al, 
unpublished results).  
We showed a difference in the strength of associations between certain 
SNPs and serum 25OHD concentration in case and control mothers. This 
difference can be interpreted as a marker of possibly several other differences 
in vitamin D genetics and metabolism between the case and control mothers. 
It is possible that these differences lead to an altered supply of vitamin D 
from the mother to the foetus, or to an altered regulation of the genes in the 
VDR controls, or both. The fact that we detected this difference in two out of 
four gene loci highlights the importance of the finding.  
It is possible that since pregnancy causes various physiological changes, it 
may prove to be one of the factors that modify associations between SNPs 
and outcome. This, however, may not explain the finding, since both case and 
control mothers were pregnant.  
The mechanism and the clinical meaning of this finding are beyond the 
data of the present study and therefore further studies are needed.  
 
 
 
5.8 HLA GENE REGION ASSOCIATES WITH SERUM 
25OHD CONCENTRATION (IV) 
 
 
Since both the HLA gene region and vitamin D have been associated with 
type 1 diabetes, we wanted to study the possible relationship between these 
two factors. Of the mothers that had serum 25OHD concentrations available, 
successful HLA genotyping was performed as follows: HLA-B of 395 
mothers, HLA-DRB1 of 501 mothers and HLA-DQB1 of 475 mothers. Due to 
high polymorphism of the HLA-B region, HLA-B alleles were grouped into 
supertypes (please see 4.5 for more information).  
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The case and control mothers were analysed as one group. In our earlier 
study (III) we, however, observed a difference between the case and control 
mothers in the strength of associations between SNPs and serum 25OHD 
concentration, therefore we checked for possible interaction according to the 
mother type. No interaction was found. 
An association was found between serum 25OHD concentration and 
HLA-B44 supertype (p=0.009) (table 4). The HLA-B44 supertype associated 
with a lower serum 25OHD concentration. In these data, we could not 
identify an association between serum 25OHD concentration and individual 
HLA-B alleles that form the B44 supertype. We did not find an association 
between HLA-DRB1 or -DQB1 alleles and serum 25OHD concentration. 
Multiple testing was addressed using the FDR approach (II). 
 
Table 4. Association of human leukocyte antigen (HLA) B supertypes, HLA-DRB1 and 
HLA-DQB1 alleles with serum 25-hydroxyvitamin D (25OHD) concentration 
amultiple testing correction with false discovery rate (FDR) approach (Benjamini-Hochberg 
step-up procedure). If the original p value was less than the Benjamini-Hochberg critical value, it 
was considered statistically significant  
*statistically significant after multiple testing correction with FDR approach.   
 
HLA-B supertype/HLA-
DRB1/HLA-DQB1 allele
  
n serum 25OHD 
concentration (nmol/l) 
p Benjamini-
Hochberg 
critical valuea 
B07 supertype 241 44.3 0.96  
B08 supertype 87 46.0 0.40  
B27 supertype 93 42.6 0.18  
B44 supertype 160 41.0 0.009* 0.02 
B62 supertype 113 
 
42.4 0.29  
DR1  140 43.0 0.52  
DR3 130 44.0 1.00  
DR4 209 43.6 0.60  
DR7 47 41.2 0.10  
DR8 91 43.0 0.43  
DR9 35 48.5 0.24  
DR11 38 44.3 0.87  
DR13 107 45.1 0.64  
DR15 96 
 
44.7 0.89  
DQ2 150 44.2 0.92  
DQ3 270 44.1 0.92  
DQ4 86 43.0 0.51  
DQ5 159 43.5 0.83  
DQ6 181 45.4 0.15  
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A trend was detected in the serum 25OHD concentrations according to how 
many B44 supertype alleles (0,1, or 2) the participants had (p for trend=0.05; 
table 5). Having two HLA-B44 supertype alleles associated with the lowest 
serum 25OHD concentrations.  
 
 
Table 5. Association of HLA B44 supertype and serum 25-hydroxyvitamin D (25OHD) 
concentration in participants carrying 0, 1 or 2 B44 supertype alleles. 
 
Number of B44 supertype alleles
  
n serum 25OHD concentration 
(nmol/l)  
p for trend 
0  235 45.7 0.05 
1   142 41.8  
2 18 37.3  
 
 
 
Our finding is novel and suggests an even stronger role for vitamin D in the 
functions of the immune system than previously proposed. It also indicates 
that the HLA gene region is one of the genetic determinants of serum 25OHD 
concentration, which has not been shown before. 
HLA polymorphism has been known for decades to associate with type 1 
diabetes and several other autoimmune diseases (Shiina et al, 2009). Since 
vitamin D has also been long suspected to have a role in the development of 
type 1 diabetes and other autoimmune diseases, the lack of previous studies 
on the relationship between vitamin D status and HLA alelles / supertypes is 
surprising. It may be that in type 1 diabetes studies, often only HLA-DRB1 
and HLA-DQB1 alleles are genotyped and thus no association has been 
found. As for studies researching the genetic determinants of serum 25OHD 
concentrations, the high polymorphism of the HLA gene region may have 
prevented the traditional GWAS to detect any associations. The relatively 
high costs of traditional HLA genotyping may also have influenced the 
possibilities to include HLA genotyping.  
The development of next-generation techniques in GWAS will also enable 
the inclusion of the HLA gene region in the analyses. This will considerably 
help evaluate the importance of the HLA polymorphisms in other diseases in 
addition to autoimmune diseases. They will also help to evaluate the 
association between vitamin D status and the HLA gene region more closely. 
Our initial aim was to study if HLA alleles that associate with type 1 
diabetes, would associate with lower serum 25OHD concentration thus 
providing a suggestion of the mechanism behind the putative association 
between vitamin D and type 1 diabetes. No association was found between 
the serum 25OHD concentrations and the HLA alleles that associate the 
strongest with type 1 diabetes (HLA-DRB1*3 and HLA-DRB1*4).  
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HLA-B*18, B*37, B*40, B*44 genes that form the HLA-B44 supertype, 
have been associated with both low and high risk for type 1 diabetes (and 
with other diseases). Of these, B*18 gene has previously been associated with 
an increased risk for type 1 diabetes, whereas the B*44 gene with a decreased 
risk (Howson et al, 2009; Noble et al, 2010). Thus, our finding does not 
suggest a causal relationship between low serum 25OHD concentration and 
type 1 diabetes risk, but further strengthens the role of vitamin D in the 
functions of the immune system. It is known, for example, that cells in the 
immune system are able to synthesise active vitamin D (1,25OHD2) (Aranow, 
2011; Guillot et al, 2010). Due to the small sample size, we could not analyse 
the association of serum 25OHD concentration with individual HLA-B 
alleles.   
The mechanism explaining our finding is not clear, but the fact that 
VDREs exist in the promoter region of at least certain HLA alleles (Cocco et 
al 2012; Israni et al 2009; Ramagopalan et al, 2009), indicates a role for 
vitamin D in the regulation of the HLA gene region related expression. At 
least some HLA-B genes are also associated with increased levels on serum 
inflammation markers (Lenna et al, 2015). It is possible that a low serum 
25OHD concentration reflects a higher “consumption” of circulating vitamin 
D as a response to an increased susceptibility for inflammation in individuals 
carrying certain HLA alleles.  
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6 DISCUSSION 
6.1 FINDINGS  
 
Our main discovery was that maternal genes in the metabolic pathway of 
vitamin D seem to modify type 1 diabetes risk in the child. Especially the 
VDR gene seems to have an important role. We did not find proof to support 
a direct relationship between maternal vitamin D status and type 1 diabetes 
risk in the child. Our study, however, showed an even more diverse role for 
vitamin D as part of the immune system through an association between the 
HLA gene region and vitamin D status.  
Our findings related with the possible role of maternal genes in early 
programming of type 1 diabetes risk in the child are novel. Our results 
indicate that the association between vitamin D and type 1 diabetes is more 
complex than previously thought. The central role of the VDR gene may 
relate to the fact that the VDR controls hundreds of genes, and in the 
presence of vitamin D deficiency, the function of the receptor may be altered.   
 
 
 
6.2 IMPORTANCE AND INTERPRETATION OF THE 
FINDINGS  
 
In this study, we had the strong advantage of being able to retrospectively 
identify mothers, whose children later developed type 1 diabetes by using the 
FMC samples that are being collected from practically all pregnant Finnish 
women. We had therefore an ideal study setting to search for vitamin D 
related differences between the case and control mothers that may have 
contributed to the disease process. 
Only one similar study exists (Sørensen et al, 2012). The lack of studies is 
understandable due to difficulties in implementing these kinds of studies. 
One approach would be to recruit a large group of pregnant women/children 
without any specific inclusion criteria, collect samples during pregnancy and 
infancy, and wait for a type 1 diabetes diagnosis in a sufficient number of 
children. This approach would require massive resources as well as demand a 
long period of time. The second approach would be to recruit a large group of 
pregnant women/children with genetically increased risk for type 1 diabetes. 
This may be done by recruiting healthy siblings of the diagnosed type 1 
diabetic patients or by screening for high-risk HLA alleles. Inclusion criteria 
based on the high-risk HLA alleles has been used, for example, in the Finnish 
Diabetes Prediciton and Prevention (DIPP) study. This approach will provide 
a sufficient number of patients more quickly, but demands considerable 
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resources as well. The third option is the one we were able to utilise; to use 
existing samples that have been collected for other purposes, and to analyse 
the samples after knowing which of the children developed type 1 diabetes.  
The Norwegian study (Sørensen et al, 2012) found an association between 
maternal serum 25OHD concentration and type 1 diabetes risk in the child 
whereas we did not. Since the maternal serum 25OHD concentrations in 
Norway were considerably higher than in our study, it needs to be considered 
whether a considerably better maternal vitamin D status than in our study 
could protect the child from type 1 diabetes. Indeed, the most promising 
results of vitamin D intervention studies have been obtained in studies using 
relatively high dose vitamin D supplementation, such as the recent study that 
showed an effect of vitamin D in controlling the symptoms of autism 
spectrum disorder (Saad et al, 2016).  
Our findings and the suggested role of maternal genes in the metabolic 
pathway of vitamin D as determinants of type 1 diabetes risk in the child are 
novel. While the phenomenon of maternal genetic factors modifying a 
disease risk in the child, independent on the child´s corresponding factors, is 
not new, the idea has not been suggested in the literature of type 1 diabetes 
research before. It is unclear whether the genetic differences between the 
case and control mothers were visible in our study because the mean serum 
25OHD concentrations were so low in all mothers. It may be, for example, 
that particular forms of the VDR gene lead to differentiated overall function 
of the VDR only when there is a lack of circulating 25OHD to be converted to 
active vitamin D (which binds to the VDR and is needed for an adequate 
function of the VDR).  
The immune system of the foetus develops throughout the pregnancy 
(Holt and Jones, 2000) and insulin-positive cells can already be detected in 
the foetal pancreas during the first trimester of pregnancy (Piper et al, 2004). 
Since type 1 diabetes can develop at a young age, it is justified to assume that 
the development of the autoimmune process may already begin during the 
foetal period. No information exists, however, on the time window during the 
foetal development that would be critical for the pathogenesis of the disease. 
 Serum 25OHD concentrations have been shown to rise through 
pregnancy (Bärebring et al, 2016; Davies-Tuck et al, 2015), but it is unclear 
whether this increase reflects actual physiological changes or for example a 
more frequent use of vitamin D containing supplements during late 
pregnancy. In mice (Shahbazi et al, 2011), however, the expression of the 
VDR markedly increases in the late pregnancy suggesting a role for vitamin D 
in the foetal development during late pregnancy.  
The fact that associations between a certain SNP and an outcome can vary 
between individuals has been shown in many studies outside type 1 diabetes 
research, but the phenomenon is still somewhat new and its meaning has not 
been fully understood. Our findings suggested that SNPs in the metabolic 
pathway of vitamin D associate differently with vitamin D status between the 
case and control mothers. Although in recent years a huge number of genetic 
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variants that associate with complex traits and diseases have been identified 
by GWAS studies, they have so far explained a surprisingly small proportion 
of the disease susceptibility. Several explanations have been suggested for the 
“missing heritability”. It seems that some of the heritability can be hidden in 
GWAS because the study populations consist of distinct sub-populations in 
which the variants have different effects. Thus, it would be important to 
analyse genetic determinants of a health outcome separately for different 
sub-populations, stratified according to relevant environmental factors or 
host characteristics, given that a justification for forming these 
sub-populations exist.   
The focus of genetic studies related with type 1 diabetes has mainly been 
on the patient, and the effect of maternal genes independent of the 
corresponding genes in the child, has not previously been proposed as a 
determinant of type 1 diabetes risk in the child. Our findings suggest a new 
window for prevention of diabetes, the target being the mother and the 
pregnancy instead of the child. Maternal genes in the metabolic pathway of 
vitamin D seem, on the basis of our results, to associate with type 1 diabetes 
risk in the child, but at present there is no evidence to support a hypothesis 
that additional vitamin D supplementation would change these genetic 
effects (although no evidence excludes this hypothesis either).  
Vitamin D supplementation would be an attractive means for preventing 
type 1 diabetes, since the prevention would not require, for example, genetic 
or autoantibody screening. These screenings are expensive and difficult to 
implement at a population level, whereas increasing the average serum 
25OHD concentrations through, for example, increased vitamin D 
fortification would be a cost-effective action that is easily put into practice. If 
vitamin D has the potential to prevent or delay type 1 diabetes, we should be 
able to see a decrease in type 1 diabetes incidence in Finland due to an 
increase in the use of vitamin D supplements (Raulio et al, 2016) and due to 
starting of vitamin D fortification (Ministry of Trade and Industry of Finland, 
2002). This has, in fact, already been investigated and it was found that an 
increase in serum 25OHD concentrations preceded a plateau in type 1 
diabetes incidence in Finland (Mäkinen et al, 2014). This is an 
epidemiological association that will need to be confirmed in well-designed 
intervention studies.  
Our finding of an association between vitamin D status and the HLA gene 
region suggests an even stronger role for vitamin D as part of the immune 
system. The mechanism of this association is beyond our study, but it can be 
speculated that certain people may be more prone to an inflammation (due 
for example to their HLA and other genetic profile, regardless of any 
inflammation-linked disease), and thus may “consume” more vitamin D, 
which is mirrored by a weaker vitamin D status. An interesting example of 
the “consumption” of vitamin D as a result of a reaction of the immune 
system is when a healthy person has surgery or delivers a baby; the serum 
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25OHD concentrations drop drastically within hours to be then normalised 
slowly within the next few months (Luxwolda et al, 2012).  
Even though the association between vitamin D and type 1 diabetes is not 
clear at present, it is important to remember that vitamin D has many 
important functions in the foetal development including the development 
and the mineral density of the bone (Viljakainen et al, 2010) and that the 
foetus is entirely dependent on the mother for an adequate vitamin D supply. 
In Finland, very little sunlight is available from the autumn to the spring. It 
has been suggested that due to evolutionary strain, to increase the vitamin D 
synthesis the light colour of the skin has evolved in the northern parts of the 
world to compensate for the low supply of vitamin D through UV radiation 
(Juzeniene et al, 2009). This can be regarded as proof of the crucial role of 
vitamin D in the body. Without any supplementation, vitamin D deficiency is 
a problem for pregnant women and to the developing foetus.  
Our findings suggest a role for the mother or pregnancy in the initiation of 
the disease process of type 1 diabetes, and therefore underline the need to 
investigate this relationship further.  
 
 
6.3 CRITICAL EVALUATION OF THE STUDY  
 
We chose to use saliva samples in our study to increase the number of 
participants. It is difficult to determine an average percentage of participants 
in Finnish medical or genetic studies, since the study settings and sample 
collection methods vary considerably. It is therefore difficult to conclude 
whether using saliva samples instead of blood samples actually increased the 
number of participants since we had more problems with the quality of the 
samples than we usually have with blood samples. In some cases there was 
too little saliva or the DNA that was extracted from the saliva was of poor 
quality. We, however, got enough participants and usable samples when 
considering our power calculations and thus consider the method of sample 
collection satisfactory. Since we also had children in our study population, 
giving a saliva sample can be considered to cause less inconvenience and thus 
a more ethical choice. 
We did not have the possibility to choose any other stage of pregnancy or 
a time-point during childhood to define vitamin D status, since the FMC 
samples are only collected during the first trimester of pregnancy in Finland. 
The development of the foetal immune system and pancreas start during the 
first trimester of pregnancy, but continue throughout the pregnancy. It is 
therefore not possible with the present knowledge to determine the adequate 
time window for early programming of tye 1 diabetes. Being able to define the 
vitamin D status only during the first trimester of pregnancy is a limitation in 
our study, but there is no reason to believe it would cause biases or errors to 
the results.  
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The results obtained through laboratory analyses are often automatically 
seen as objective, accurate or as the “truth”, compared to data collected 
through, for example, questionnaires or other methods. This is an impression 
that needs to be considered in a critical manner. The laboratory analyses 
without a careful quality control and understanding of the nature of the 
analyses can lead to substantial errors. These errors are extremely difficult to 
notice, if the results are evaluated by a person without the appropriate 
education or if the quality control has been inadequately described, for 
example, in a scientific publication. In the manuscript review process, the 
reviewers may concentrate more on the presented results and their 
significance without questioning the justification to rely on the presented 
results in the first place. Serum 25OHD concentration analytics is a good 
example in this context due to the relative complexity of the analysis. We had 
a relatively strong quality control in our laboratory analyses, nevertheless it 
is important to understand that the exact numbers of serum 25OHD 
concentrations do not represent the “truth” and that our results cannot be 
compared to other results obtained with different methods.  
There are number of genes related to vitamin D metabolism and a 
number of SNPs in each of these genes. In this study only a small selection of 
SNPs in some of these genes were analysed. It is possible that if we had 
selected the SNPs differently, we would have received different results. The 
extent of alternatives when planning the study increased our need to create 
grounds for selecting the SNPs. We chose to select those SNPs in the 
metabolic pathway of vitamin D that had been associated with vitamin D 
status, type 1 diabetes or both. Although some interesting findings were 
made with this particular selection of SNPs, it is useful to take into account 
that the findings present only a small part of the overall picture of the 
relationship between genes in the metabolic pathway of vitamin D and type 1 
diabetes. Our findings can be considered as markers of several other possible 
differences and as a justification to further studies in the field.   
In genetic association studies but also in epidemiological association 
studies in general, there is a possibility of false positive findings when testing 
several associations. This problem needs to be addressed and many 
researchers do this by using some of the various multiple testing correction 
methods described in the literature. Using multiple testing correction is not a 
specific procedure but simply means setting a stricter significance threshold 
for a finding than the commonly used p value of lower than 0.05. Different 
multiple testing correction methods accept distinct level of uncertainty when 
reporting the true findings. When hundreds or thousands of associations are 
tested without a pre-specified biologically justified hypothesis, the usefulness 
of using these corrections may be easy to understand. When there is a 
biologically justified hypothesis, the question is more complex. In our study, 
all of our association analyses were based on at least some kind of 
physiological relationship or a proposed mechanism, explaining why we 
chose to do just these particular analyses. Nevertheless, since our findings 
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were novel and at least partly unexpected, we felt a need to confirm the 
reliability of the results and to simplify the evaluation of our results to 
anyone exploring our work. Therefore, we decided to correct for multiple 
testing and reported only those associations that remained significant after 
the correction. It is important, however, to note that using multiple testing 
correction will not guarantee true meaningful associations nor does it mean 
that the findings that are not significant after the correction are always false 
positives. It is possible that a strict demand to use multiple testing correction 
will translate into the researchers not reporting all associations tested 
(Schulz and Grimes, 2005) and therefore, the careful evidence-based 
interpretation of the results by the researcher should be the most important 
demonstration or proof for the significance of the results, whether or not a 
correction has been used.  
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7 CONCLUSIONS AND FUTURE 
PERSPECTIVES 
1. No association was found between maternal vitamin D status during 
the first trimester of pregnancy and the risk for type 1 diabetes in the 
child.   
 
2. Vitamin D deficiency was common among pregnant women.  
 
3. Maternal genes in the metabolic pathway of vitamin D associated with 
type 1 diabetes in the child, independent of the corresponding factors 
in the child.  
 
4. The HLA gene region associated with serum 25OHD concentration. 
 
 
 
 
FUTURE RECOMMENDATIONS 
 
1. The effect of higher (but safe) vitamin D supplementation for 
pregnant women or infants on the type 1 diabetes risk should be 
evaluated.  
 
2. The current vitamin D status of the pregnant women in Finland 
should be investigated.  
 
3. It should be evaluated whether children with autoantibodies have a 
weaker response to vitamin D supplementation than control children 
with no autoantibodies.  This would suggest that vitamin D takes part 
in the ongoing autoimmune process of these children. 
 
4. It should be investigated whether the genetic differences in vitamin D 
metabolism between mothers of diabetic and non-diabetic children 
are reflected as differences in the vitamin D status of the newborn, for 
example by using blood samples from the umbilical cord    
 
5. It should be investigated whether the genotype differences between 
the case and control mothers seen in our study are dependent on the 
vitamin D status e.g seen only in vitamin D deficient subjects. 
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6. It should be clarified whether HLA-B44 supertype alleles associate 
with a higher predisposition to inflammation and thus explain the 
association between serum 25OHD and HLA-B44 supertype. 
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